Introduction {#s1}
============

RNA silencing is a host defense mechanism to combat invading nucleic acids. One type of RNA silencing is referred to as post-transcriptional gene silencing (PTGS). In PTGS, double-stranded RNAs (dsRNAs) are processed by Dicer-like ribonucleases into small-interfering RNAs (siRNAs). Mature siRNAs are incorporated into an Argonaute (AGO)-centered RNA-induced silencing complex (RISC) to regulate expression of target genes through RNA cleavage or translational repression. PTGS has evolved as a universal defense response toward all viruses because dsRNAs can result from intermediates in RNA virus replication, highly structured RNA virus genomes, or from viral transcripts. To evade this surveillance mechanism, virtually all plant viruses are known to encode suppressor proteins that are able to block different key steps of the PTGS pathway ([@bib12]).

While the host/virus battle at the PTGS level has been well appreciated, virus suppression at a transcriptional gene silencing (TGS) level is poorly understood. In eukaryotes, the nuclear DNA is wrapped onto histone octamers to constitute chromatin. The chromatin undergoes various DNA and histone methylations, and these modifications have variable effects on gene expression depending on the precise residues, contexts, and modification complexity. Histone methylation takes place on lysine and arginine residues of the amino-terminal tails ([@bib28]; [@bib23]). The prevailing dogma is that histone 3 lysine 4 tri-methylation (H3K4me3) is mostly associated with transcriptionally active euchromatin, while H3K9me2 and H3K27me3 are repressive marks ([@bib11]; [@bib20]). Histone methylation is catalyzed by SET domain containing methyltransferases, specifically, H3K9me2 is deposited by *Arabidopsis* Su(var)3-9 homolog 4, Kryptonite (KYP) ([@bib14]), and its paralogs (SUVH5,6), while H3K27 methylation is carried out by the Polycomb repressive complex 2 (PRC2)*,* which includes Curly Leaf (CLF) ([@bib31]; [@bib66]). Local H3K9me2 and H3K27me3 can spread over wide regions to elicit heterochromatin configuration. In animals, the propagation of histone methylation entails co-repressor heterochromatin protein 1 (HP1), whereas in plants, KYP acts synergistically with DNA methyltransferases (i.e., Chromomethylase 3 \[CMT3\]) to constitute a mutually reinforcing cycle of DNA and histone methylation to secure TGS ([@bib16], [@bib14]).

Histone methylation not only regulates endogenous gene expression but also invasive DNAs such as transposons and viruses ([@bib38]). Plant DNA viruses, exemplified by Geminivirus, form minichromosomes in the host ([@bib24]). Both Geminivirus DNA and associated histones are methylated in infected cells, whereas viral methylation is reduced in methylation-deficient hosts, methylation-compromised *Arabidopsis* mutants are hypersusceptiple to Geminivirus infection and show exacerbated disease symptoms ([@bib42]). Thus, plants appear to employ methylation of viral chromatin to limit viral replication and transcription ([@bib1]; [@bib40]). On the other hand, Geminiviruses encode a multi-functional protein called transcriptional activation protein (TrAP/AL2/AC2) that counters the epigenetic defense ([@bib42]; [@bib6]). It has been shown that TrAP inhibits adenosine kinase (ADK) ([@bib54]). ADK catalyzes the synthesis of 5′ AMP from adenosine and ATP, a process that promotes the regeneration of S-adenosyl-methionine (SAM), the major methyl donor in the cell ([@bib34]; [@bib6]). Consequently, the TrAP-mediated inhibition of ADK activity likely impedes downstream trans-methylation events, including viral chromatin methylation in the nucleus ([@bib4]; [@bib6]). In parallel, some Geminivirus encode a TrAP positional homolog, named C2, that is able to stabilize SAM decarboxylase 1 to downregulate the methyl group metabolism ([@bib65]). It seems that interfering with the methyl cycle is a common suppression mechanism for Geminivirus-encoded TrAP/AL2/C2 proteins. In addition, C2 also subverts the activity of COP9 signalosome to inhibit jasmonate signaling ([@bib33]), suggesting its multiple functions in viral counter-defense.

Here, we investigated the suppression mechanism of TrAP proteins, encoded by two Geminivirus members, *Tomato Golden Mosaic Virus* (TGMV) and *Cabbage Leaf Curl Virus* (CaLCuV). We found that constitutive expression of TGMV-*TrAP* in *Arabidopsis thaliana* caused morphological abnormalities that mimic loss-of-function mutants of numerous TGS components including *lhp1* (*like-heterochromatin1*) and *clf*. Microarray analyses of *TrAP* transgenic plants and *lhp1* mutants revealed a substantial overlap in reprogrammed host genes at a genome-wide level. Through biochemical screening, we identified KYP as the bona fide target of TrAP. We demonstrated in vitro that TrAP binds to the catalytic domain of KYP and inhibits its enzymatic activity; while in vivo, *TrAP* decreases the repressive H3K9me2 marks and H3K9me2-dependent CHH methylation in gene-rich regions. We also found that KYP directly associates with the Geminivirus minichromosome and deposits H3K9me2 marks on viral chromatin. In addition, *kyp* mutants but not wild-type plants sustain low systemic infection of CaLCuV lacking TrAP protein. Taken together, we propose that KYP-catalyzed H3K9me2 is a line of the innate immunity against invading DNA pathogens, and Geminivirus TrAP functions to inactivate KYP to counter host defense. Thus, this study provides new insight into the host--virus interaction at the TGS level.

Results {#s2}
=======

TGMV-encoded TrAP causes developmental abnormalities in *Arabidopsis* but not through miRNA pathway {#s2-1}
---------------------------------------------------------------------------------------------------

To study the suppression mechanism of TrAP, we generated 235 *Arabidopsis* transgenic lines overexpressing full-length TGMV TrAP, with or without Flag-Myc4, 3HA, or CFP epitopes. These transgenic plants were confirmed by northern (data not shown) or western blot assays ([Figure 1A](#fig1){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Importantly, the majority of the transgenic lines exhibited developmental abnormalities consisting of short statues, strongly upward curled cotyledons and true leaves ([Figure 1B](#fig1){ref-type="fig"}). Moreover, these overexpressing lines exhibited early flowering compared to wild-type (WT) plants. These phenotypes were morphologically distinct from loss-of-function mutants of *ADK1 ADK2* ([@bib56]; [@bib34]), *SnRK1* ([@bib46], [@bib45]), *PEAPOD2* ([@bib30]), and *rgsCaM* ([@bib8]), a calmodulin-like protein, which are also targets or partners of TrAP. This result indicated that TrAP exerts some novel cellular function (s).10.7554/eLife.06671.003Figure 1.TrAP caused developmental abnormalities in Arabidopsis but not through miRNA pathway.(**A**) Western blot analysis of *35S-TrAP-3HA* and *35S-TrAP-CFP* transgenic lines. Arrows indicate the locations of the tagged TrAP proteins; \* Cross-reaction band serves a loading control. (**B**) Morphological defects of Arabidopsis transgenic plants expressing *35S-TGMV TrAP*. Photographs were taken of 10-day seedlings. (**C**) RNA blot analysis of *PHB* and *AGO1* transcripts in the *TrAP* overexpression transgenic plants using gene-specific random-labeled probes. *25S rRNA* is a loading control. (**D**) sRNA blot analysis of miRNA and miRNA\* in the *TrAP* overexpression transgenic plants. Total RNA was prepared from a pool of T2 transgenic plants (n \> 50 for each line). sRNA blots were probed using 5′ end ^32^P-labeled oligonucleotide probes complementary to the indicated miRNA or miRNA\*. *5S rRNA* and *tRNA* are a loading control. All the samples were run in the same gel; but the lane order of miRNA\*s was rearranged to match that of miRNAs. (**E**) sRNA blot analysis of miR165 loading into Arabidopsis RNA-induced silencing complexes (RISCs). RNA was extracted from flowers or Flag-AGO1 immunoprecipitates of transgenic plants harboring *35S-TrAP* or *35S-TrAP-3HA* in *ago1-36; P*~*AGO1*~*-Flag-AGO1* background and *ago1-36; P*~*AGO1*~*-Flag-AGO1* control plants ([@bib3]). Top panel, total RNA; middle panel, each lane contained sRNA associated with Flag-AGO1 immunoprecipitated from 0.4 g of flowers. Bottom panel, the input and immunoprecipitate of Flag-AGO1 were analyzed by Western blot assays in the same samples for sRNA blots. A cross-reacting band (\*) was used as a loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.003](10.7554/eLife.06671.003)10.7554/eLife.06671.004Figure 1---figure supplement 1.sRNA blot analysis of additional miRNAs and siRNA in the TrAP overexpression transgenic plants.Total RNA was prepared from a pool of T2 transgenic plants (n \> 50 for each line). sRNA blots were probed using 5′ end ^32^P-labeled oligonucleotide probes complementary to the indicated miRNAs or siRNA. U6 serves as a loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.004](10.7554/eLife.06671.004)

Developmental anomalies of transgenic plants expressing viral suppressors have been associated with interruption of the miRNA pathway. To test this, we compared expression levels of several miRNAs and their targets between Col-0 wild-type and *TGMV TrAP* transgenic plants. Plants expressing *Cucumber mosaic virus*-encoded 2b suppressor (Zhang et al., 2006) and *ago1-27*, a hypomorphic allele of *ago1* ([@bib35]), were used as controls. We observed that the accumulation of miR165 and miR168 and their targets, *PHB* and *AGO1* transcripts, in the *35S-TGMV TrAP* lines was comparable to the amount in wild-type plants ([Figure 1C,D](#fig1){ref-type="fig"}). We further confirmed that loading of miRNAs into AGO1-centered RISCs was not affected by TrAP ([Figure 1E](#fig1){ref-type="fig"}). The same results were obtained with miR167, miR159, and ta-siRNA480/255 and their corresponding targets ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Thus, unlike most of previously reported viral suppressors, TrAP does not act on the miRNA pathway.

TrAP genetically interrupts the TGS pathway {#s2-2}
-------------------------------------------

To study how *TrAP* altered plant development, we mined publicly available databases and literature for the molecular and morphological phenotype of *35S-TrAP* lines. We found that *35S-TrAP* transgenic lines phenocopied several mutants in the epigenetic pathway including *lhp1* ([@bib27]) ([Figure 2A](#fig2){ref-type="fig"}) and *clf* mutants ([@bib7]), with respect to the early flowering and upward curling of leaves. CLF belongs to PRC2, a complex that catalyzes the deposition of H3K27me3 marks. LHP1 ([@bib37]), on the other hand, associates to silent genes in euchromatin and directs the spreading of the silent status to adjacent loci ([@bib53]; [@bib60], [@bib62]; [@bib19]; [@bib66]). Thus, coordinate activities of CLF and LHP1 result in chromatin methylation and transcriptional repression ([@bib19]).10.7554/eLife.06671.005Figure 2.TrAP is genetically involved in the TGS pathway.(**A**) *35S-TrAP* transgenic plants phenocopied *lhp1* mutants. Photographs were taken of 15-day seedlings. (**B**, **C**) Microarray results were validated by qRT-PCR analysis. Only 12 randomly selected loci were shown. (**D**) Gene ontology analysis of the *TrAP-*regulated DEGs. The numbers adjacent to the pies represent the ratio of genes in each category over the total DEGs. (**E**) Genome-wide overlapping of the genes regulated by *TrAP* and loss-of-function *lhp1*. White and black numbers correspond to upregulated and downregulated genes, respectively. Maroon number indicates the genes that are differentially deregulated in both genotypes. (**F**) Heatmap of the commonly deregulated genes in the *35S-TrAP* and *lhp1* lines. The typical gene-ontology categories are shown on top. (**G**, **H**) Microarray and RNA blot analyses of epigenetically regulated flowering genes in the *TrAP* transgenic lines and *lhp1* mutants. *Cyt450* is a control. (**I**) qRT-PCR analysis of TEs in heterochromatic regions in the *lhp1* mutant and *TrAP* transgenic lines.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.005](10.7554/eLife.06671.005)

We examined global expression profiles of 7-day-old *35S-TrAP* transgenic plants compared to Col-0 wild-type using an Affymetrix ATH1 GeneChip and identified 586 genes that are differentially expressed in the *35S-TrAP* transgenic plants (q \< 0.005). Of these, 295 transcripts were elevated whereas 291 were reduced ([Figure 2E](#fig2){ref-type="fig"}). We performed real-time PCR and RNA blot assays to validate the microarray results for the differentially expressed genes (DEGs). Among 25 genes randomly tested, we confirmed the ATH1 results for 24, indicating that the microarray results were reliable ([Figure 2B,C](#fig2){ref-type="fig"}; data not shown). Gene-Ontology (GO) analysis placed the DEGs into seven functional categories ([Figure 2D](#fig2){ref-type="fig"}; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}): hormone response (86 genes), stress response (94 genes), development regulation (50 genes), transcriptional regulation (20 genes), RNA metabolism (13 genes), post-translational modification (36 genes), and general metabolism (182 genes), plus a set of 105 un-annotated genes ([Figure 2D](#fig2){ref-type="fig"}; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}).

Then, we compared the DEG profiles of the *TrAP* overexpression lines and loss-of-function *lhp1* mutant ([Figure 2E,F](#fig2){ref-type="fig"}; [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Transcriptome analysis revealed that out of 295 genes significantly upregulated in the *35S-TrAP* transgenic lines, 120 (40.7%) were also upregulated in *lhp1* mutant. This is significantly greater than 1.28% expected by chance (p \< 2.2e^−16^, Pearson\'s Chi-squared test). Interestingly, among the co-upregulated genes are a group of flowering-stimulated transcriptional factors including the key flowering-time integrator, *FT,* and 12 other genes such as *TFL1*, *AGL5*, and *AGL9* ([@bib19]) ([Figure 2F--H](#fig2){ref-type="fig"}; [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}; [Supplementary file 8](#SD8-data){ref-type="supplementary-material"}) clustered in the transcriptional regulation category. Importantly, all these genes are regulated through epigenetic pathways and account for the early flowering phenotypes of *lhp1* mutant and possibly of *TrAP* transgenic plants as well ([@bib22]). Other highly represented categories included 31 genes involved in aging and 116 genes engaged in stress responses ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Notably, the stress-responsive genes included genes specific to biotic stress such as *PR4*, *WRKY18*, *FLS2*, and *PDF1.2*; additionally, genes related to chemical stress, such as *PTR3* and *TAT3*, were also identified. Thus, constitutive expression of *TrAP* could trigger plant senescence and innate defense pathways, and this activation is potentially through interference with the *LHP1*-related epigenetic silencing.

Similarly, out of 291 genes significantly downregulated in the *35S-TrAP* transgenic lines, 137 (47.1%) were also repressed in *lhp1* mutant. This is significantly greater than 1.25% expected by chance (p \< 2.2e^−16^, Pearson\'s Chi-squared test) ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Genes related to auxin response were of special interest. Of the 32 DEGs involved in the auxin pathway, 29 genes were downregulated in the *35S-TrAP* transgenic plants, classified as small auxin upregulated mRNAs (*SAUR*s). These results suggested a possible hyposensitivity to auxin in *lhp1* mutants and *TrAP* transgenic plants, which could explain the smaller statues of both genotypes. Consistent with this hypothesis, numerous auxin-repressed loci including *PS2* and aging genes like *TET9*, *SAG13*, and *SRG1* were upregulated in both lines. Concomitantly, six genes related to cell growth and five genes engaged in cell wall loosening were also repressed. Significant genome-wide overlap of *35S-TrAP* and *lhp1* loss-of-function-responsive genes suggested that *TrAP* might be genetically involved in the *LHP1*-related TGS pathway.

Since LHP1 is believed to reside in euchromatic regions, we wondered whether *TrAP* also deregulates expression of heterochromatic loci. To this end, we selected numerous transposable elements (TEs) that were not recovered from the microarray assays and assessed them directly by qRT-PCR. Excitingly, most of the tested transposons were transcriptionally active ([Figure 2I](#fig2){ref-type="fig"}), further suggesting that *TrAP* indeed inhibits the TGS pathway, in both euchromatic and heterochromatic regions.

KYP is a bona fide target of TrAP {#s2-3}
---------------------------------

Given that *TrAP* transgenic plants phenocopied several TGS mutants and displayed transcriptional activation of heterochromatic loci, we hypothesized that TrAP epistatically regulates a TGS integrator (s), indirectly leading to deregulation of the epigenetic marks. Analysis of the microarray data challenged this possibility as no significant changes in the transcripts of any canonical TGS components were revealed ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}). An alternative hypothesis was that TrAP directly interferes with the function of a TGS component (s). To test this in an unbiased manner, we used luciferase complementation imaging (LCI) assay to screen 34 TGS-related proteins and some other cellular factors for TrAP interaction ([@bib65]) ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). In the LCI experiments, the N- and C-terminal parts of firefly luciferase (NLuc and CLuc) are fused to different test proteins to be transiently expressed in *Nicotiana benthamiana* (*N. benthamiana*). When NLuc and CLuc are brought together through interaction of the test proteins, catalytic activity is restored and recorded through CCD camera. In our LCI screening, we recovered LHP1 and KYP, a SUVH-type H3K9me2 methyltransferase, suggesting that TrAP is physically close to LHP1 and/or KYP proteins in vivo ([Figure 3B](#fig3){ref-type="fig"}). Next, we carried out confocal microscopy imaging assays. TrAP co-localized with both LHP1 and KYP in scattered but not yet clearly defined nuclear foci, whereas co-expression of TrAP-CFP and other YFP-tagged proteins in *N. benthamiana* cells did not show such patterns ([Figure 3C](#fig3){ref-type="fig"}). These observations further suggested that TrAP was in the same complexes as LHP1 or KYP. To further examine if TrAP interacted with these proteins, we conducted co-immunoprecipitation (Co-IP) assays ([Figure 3D](#fig3){ref-type="fig"}). Interestingly, we validated the TrAP-KYP interaction ([Figure 3D](#fig3){ref-type="fig"}) but not TrAP-LHP1 (data not shown), indicating that the LCI signal resulting from the TrAP-LHP1 combination likely involved additional cofactors between TrAP and LHP1 in vivo ([Figure 3B](#fig3){ref-type="fig"}). Alternatively, TrAP-LHP1 interaction might be transient or unstable in our stringent co-IP condition. We observed that expression of CLuc-HA3-KYP in *N. benthamiana* yielded truncated proteins of various lengths that accumulated to comparable levels as the full-length protein; only the full-length KYP showed specific interaction with TrAP, implying the KYP C-terminal domain as the interaction interface with TrAP ([Figure 3D](#fig3){ref-type="fig"}). We further confirmed the in vivo TrAP-KYP interaction by Förster resonance energy transfer-acceptor bleaching (FRET-AB), using TrAP-CFP as a donor and YFP-KYP as an acceptor. Shortly, FRET involves the energy transfer from an excited donor to an adjacent acceptor when the fluorophores are less than 10 nm apart. If the fluorophores are coupled, the excited donor leads to acceptor emission; bleaching the acceptor allows the emission of the donor to be measured ([Figure 3E](#fig3){ref-type="fig"}). Consecutive cycles of YFP-KYP bleach/recovery correlated with release/quench on the TrAP-CFP signal ([Figure 3E,F](#fig3){ref-type="fig"}); the positive FRET-AB (CaLCuV-TrAP 2.699 ± 0.23, TGMV-TrAP 3.8228 ± 0.58, p \< 0.05) corroborated TrAP-CFP/YFP-KYP interaction ([Figure 3G](#fig3){ref-type="fig"}). To examine whether TrAP interacted with KYP under physiological conditions, we isolated TrAP complexes through two-step immunoprecipitation ([@bib67]) from stable transgenic plants expressing *Flag-Myc4-TrAP* under the inducible promoter (*XVE*) ([@bib68]) followed by mass spectrometry analysis. A total of 624 peptides representing 288 unique sequences were recovered from the TrAP sample; of those, 31 unique peptides matched specifically to KYP/SUVH4 and were not found in control immunoprecipitates using Col-0 plants ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Together, all these assays clearly indicated that TrAP and KYP interact in vivo.10.7554/eLife.06671.006Figure 3.TrAP interacts with KYP in vivo.(**A**) Schematic representation of the luciferase complementation imaging assay shows the different combinations of infiltrated constructs that were fused either to N-terminal (NLuc) and C-terminal (CLuc) regions of luciferase. (**B**) Screening of host factors targeted by TrAP. The infiltration positions of the constructs (red arrows) and luminescence signal resulting from the protein--protein interaction in a leaf are shown. FTSZ and LOM2 serve as negative controls. (**C**) Confocal imaging assays show the co-localization of TrAP-CFP with YFP-KYP and YFP-LHP1 in the nuclei in *Nicotiana benthamiana*. FTSZ serves as a negative control. (**D**) Specific interaction between KYP and TrAP was confirmed in *N. benthamiana* by co-immunoprecipitation (Co-IP). Constructs harboring *35S-Myc-TrAP-nLuc* and *cLuc-HA-KYP* were co-infiltrated in *N. benthamiana* leaves. IP was conducted using anti-Myc antibody. Western blot analyses were done with the crude extract (input) and the IP products using anti-Myc or -HA antibodies. Truncated versions (red arrows) serve as an internal control. (**E**) Exemplary imaging of FRET assays of TrAP-CFP and YFP-KYP co-expressed in a nucleus. The nucleus is irradiated with 458 nm laser to excite the CFP fluorophore. Three regions were selected for the assay: \#1, autofluorescence control, \#2 fluorophore decay control, and \#3, FRET-acceptor bleaching test. Regions \#1 and \#3 were treated with pulses of 514 nm laser to bleach the YFP fluorophore. The CFP signal is then visible in region \#3 when the emission of CFP is dequenched. (**F**) Quantification of the signals from each fluorophore observed during FRET-AB experiment in **E**. (**G**) FRET is positive for YFP-KYP paired with the CFP-tagged TrAPs from either CaLCuV or TGMV.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.006](10.7554/eLife.06671.006)10.7554/eLife.06671.007Figure 3---figure supplement 1.Mass spectrometry analyses confirmed endogenous KYP as a bona fide TrAP-interacting partner.(**A**) β-estradiol Inducible expression of Flag-4Myc-TrAP protein in Arabidopsis transgenic lines (**B**) 31 peptides (green) uniquely match to the KYP sequence. (**C**) Description of recovered peptides matching KYP/SUVH4.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.007](10.7554/eLife.06671.007)

TrAP binds to the catalytic domain of KYP {#s2-4}
-----------------------------------------

We performed in vitro pull-down assays to examine whether TrAP interacts directly with KYP. We found that maltose-binding protein (MBP)-KYP, but not MBP and other MBP-tagged control proteins, was able to pull down GST-tagged TGMV- and CaLCuV-encoded TrAP proteins ([Figure 4A,B](#fig4){ref-type="fig"}). This interaction was specific as MBP-KYP was unable to pull down GST protein alone. Notably, we did not observe direct LHP1-TrAP interaction in the parallel pull-down experiments ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); and this result was consistent with the in vivo Co-IP experiments. From N- to C- termini, KYP contains SRA, PreSET, SET, and PostSET domains. To further define the protein domain (s) responsible for the specific interaction, we generated five truncations of KYP ([Figure 4C](#fig4){ref-type="fig"}). Pull-down assays showed that the SET domain interacted with TrAP proteins from both TGMV and CaLCuV at a higher affinity, whereas SRA domain might interact with CaLCuV TrAP at a reduced affinity in vitro ([Figure 4D--F](#fig4){ref-type="fig"}). These results were consistent with the results of the in vivo Co-IP experiments in which only full-length KYP, but not C-terminal-truncated versions, could recover TrAP ([Figure 3D](#fig3){ref-type="fig"}). Recent structural analysis on KYP revealed that SET and pre-SET domains constitute two modules: one forms a narrow pocket harboring the H3 tail (1--15aa), whereas the other binds the SAM cofactor, together with the post-SET domain ([@bib14]). Because the post-SET domain does not seem to contribute to the KYP-TrAP interaction, TrAP could potentially occupy the histone-binding cavity ([Figure 4F](#fig4){ref-type="fig"}).10.7554/eLife.06671.008Figure 4.TrAP interacts directly with KYP through the SET domain.(**A**, **B**) In vitro pull-down assays showed that KYP specifically interacted with TGMV TrAP (**A**) and CaLCuV TrAP (**B**). Left panel, Coomassie brilliant blue R250 staining of the proteins shows their mobility. Right panel, output of in vitro pull-down assays. All His-MBP-tagged bait proteins and His-GST-tagged prey proteins were purified from *Escherichia coli* using Ni-NTA columns. In all assays, 2.5 μg of prey proteins were pulled down with the indicated bait proteins (2.5 μg each) using amylose resin. The recovered MBP-tagged bait proteins were monitored by Coomassie brilliant blue R250 staining. All the experiments were done at the same time, and the samples were run in the same gels. The spacers in the images indicate digital rearrangements of the pictures. The output of the GST-tagged prey proteins was analyzed by western blot using a monoclonal anti-GST antibody. (**C**) Schematic diagram of full-length and truncated forms of KYP. The numbers on the left refer to the amino acid residues in KYP protein. Locations of SRA, pre-SET, SET, and post-SET domains are shown. (**D**) In vitro pull-down assays of truncated KYP proteins and TrAPs. The experiments were done as in (**A**, **B**). The GST negative control was loaded in the lanes marked with (\*). (**E**) Summary of interaction between the truncated KYP proteins and TrAP encoded by TGMV and CaLCuV. (**F**) Model of possible KYP-TrAP interaction based on the experimental results from panels **D** and **E**. KYP structure was generated in Chimera from PDB: 4QEN data set ([@bib15]), domains are color coded and indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.008](10.7554/eLife.06671.008)10.7554/eLife.06671.009Figure 4---figure supplement 1.TrAP does not interact with LHP1 in vitro.In vitro pull down assays of GST-TrAP by MBP-LHP1 is shown. Left panel, Coomassie brilliant blue R250 staining of the proteins shows their mobility. Right panel, output of in vitro pull-down assays. The recovered MBP-tagged bait proteins were monitored by Coomassie brilliant blue R250 staining. The output of the GST-tagged prey proteins was analyzed by western blot using a monoclonal anti-GST antibody. TrAP dimerization is shown as positive control. 2.5 μg of prey proteins were pulled down with the indicated bait proteins (2.5 μg each).**DOI:** [http://dx.doi.org/10.7554/eLife.06671.009](10.7554/eLife.06671.009)10.7554/eLife.06671.010Figure 4---figure supplement 2.TrAP directly interacts with KYP paralogs SUVH2, 5, and 6.In vitro pull down assays. Left panel, coomassie brilliant blue R250 staining of the proteins shows their mobility. Right panel, output of in vitro pull-down assays. The recovered MBP-tagged bait proteins were monitored by Coomassie brilliant blue R250 staining. The output of the GST-tagged prey proteins was analyzed by western blot using a monoclonal anti-GST antibody. SUVH4/KYP was used as a positive control. 2.5 μg of prey proteins were pulled down with the indicated bait proteins (2.5 μg each). All the experiments were performed simultaneously and run in two separate gels.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.010](10.7554/eLife.06671.010)

Since the SET domain is well conserved among histone methyltransferases (HMTase) ([@bib31]), we next investigated whether TrAP interacts with KYP paralogs. In vitro pull-down assays showed that TrAP indeed interacted with numerous tested HMTases (SUVH2, 5, and 6) ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Notably, loss-of-function mutants of *SUVH2* display early-flowering phenotype, suggesting that TrAP might target this protein in vivo as well.

TrAP inhibits the catalytic activity of KYP in vitro {#s2-5}
----------------------------------------------------

The specific interaction of TrAP with the catalytic SET domain of the SUVHs prompted the question of whether TrAP affects KYP activity. To test this, we set up an in vitro reconstitution of H3K9 methylation using His-GST-KYP purified from *Escherichia coli* as the enzyme source, recombinant histone 3 as the substrate, and methyl-^14^C-SAM as the methyl donor ([Figure 5A](#fig5){ref-type="fig"}). Under our experimental conditions, 1 µM GST-KYP methylated 3 µM of histone 3 in less than 5 min at 37°C, as detected by saturation of the radioactive signal ([Figure 5B](#fig5){ref-type="fig"}). Excitingly, incubation of His-GST-KYP with His-MBP-TrAP from either TGMV or CaLCuV reduced the initial velocity of KYP transmethylation activity in a dose-dependent fashion, whereas His-MBP alone did not affect KYP catalysis ([Figure 5B](#fig5){ref-type="fig"}). Quantification of signal intensity revealed that the TrAP-KYP molar ratio of 2 was enough to cause approximately 50% inhibition of KYP activity (half maximal inhibitory concentration \[IC~50~\]) ([Figure 5C](#fig5){ref-type="fig"}). Thus, our results indicated that TrAP potently inhibited the catalytic function of the HMTase.10.7554/eLife.06671.011Figure 5.TrAP inhibited HMTase activity of KYP in vitro.(**A**) Coomassie staining of purified proteins uses for the assays. (**B**) In vitro HMTase reconstitution assays with different molar ratio of MBP and MBP-TrAP proteins (0--10×) relative to GST-KYP. The recombinant KYP was incubated without (buffer only) or with the indicated proteins before addition of histone 3 and C^14^-SAM. The reactions were done in a 6-min time course; aliquots were resolved in 18% SDS PAGE and stained with Coomassie blue R250 to show histone 3 input (top panels). The dried gels were auto-radiographed to detect ^14^C-methylated histone 3. (**C**). Plotting of KYP initial velocity vs TrAP/KYP molar ratio. The initial velocity was calculated from the slope of the linear range in the signal vs time plot for each assay, and then the values were normalized using the non-inhibitor control as a standard of 1 to obtain the relative initial velocity with standard deviation (SD) from at least three biological repeats. The relative initial velocity is plotted as a function of inhibitor:enzyme molar ratio in a logarithmic scale of base 2.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.011](10.7554/eLife.06671.011)

TrAP reduces H3K9me2-repressive marks in vivo {#s2-6}
---------------------------------------------

Given that in vivo TrAP genetically interferes with the TGS pathway, and in vitro it physically interacts with HMTases (KYP, SUVH2, 5, 6) and inhibits the activity of KYP, we wondered whether TrAP alters KYP function in vivo. To address this question, we conducted chromatin immunoprecipitation (ChIP) analyses of H3K4me3, H3K9me2, and K3K27me3 marks ([Figure 6](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}; [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}) on numerous KYP-regulated TEs ([Figure 6A](#fig6){ref-type="fig"}) in TrAP overexpression plants as compared to Col-0, *ddm1*, *kyp*, and *lhp1* control plants. Remarkably, all tested loci in *TrAP* transgenic lines displayed consistent reduction of H3K9me2 and H3K27me3, whereas changes of H3K4me3 were variable. This molecular phenotype mimicked *kyp* mutant at all tested loci, but not lhp1 mutant. This result indicated inhibitory effect of TrAP on KYP activity on the TEs in vivo.10.7554/eLife.06671.012Figure 6.ChIP-qPCR analyses of H3K4me3, H3K9me2, and H3K27me3 in TrAP-regulated loci in vivo.(**A**) TrAP-activated transposons in heterochromatic regions contained reduced H3K9me2 and H3K27me3 but did not show consistent variation in H3K4me3 marks. (**B**) *TrAP*-upregulated flowering genes showed consistently reduced H3K9me2 and H3K27me3 marks compared to wild-type Col-0. (**C**) TrAP-downregulated genes displayed variable changes of H3K9me2 and H3K27me3 marks and no obvious changes of H3K4me3 mark. (**D**) Tubulin (*TUB8*) was used as internal control for all the ChIP experiments; the percentage enrichment vs input is shown. ChIP assays were conducted on 11-day-old seedlings using antibodies specific for H3K9me2 (Abcam, Cat\# ab1220), H3K27me3 (Millipore, Cat\# 07-449), and H3K4me3 (Millipore, Cat\# 04-745). Enrichment of H3K4me3 and H3K27me3 in each locus is normalized to that of *TUB8*; H3K9me2 enrichment is plotted as percentage of input. The standard deviation (SD) was calculated from at least three biological repeats.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.012](10.7554/eLife.06671.012)10.7554/eLife.06671.013Figure 6---figure supplement 1.Western blot analysis to show specificity of antibodies used for ChIP assays in the study.Crude extract (**A**) and isolated nuclei (**B**) were probed with antibodies against histone 3, H3K9me2 (Abcam Cat\# ab1220), H3K27me3 (Millipore Cat\# 07-449) and H3K4me3 (Millipore Cat\# 04-745), respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.013](10.7554/eLife.06671.013)10.7554/eLife.06671.014Figure 6---figure supplement 2.ChIP-PCR assays for selected flowering genes and heterochromatic loci confirm ChIP-qPCR.(**A**) ChIP-PCR analysis of various histone 3 modifications in flowering genes in different genetic backgrounds. (**B**) ChIP-PCR analysis of various histone 3 modifications in TEs in different genetic backgrounds. ChIP assays were conducted on 9-day-old seedlings using antibodies specific for H3K9me2 (Abcam Cat\# ab1220), H3K27me3 (Millipore Cat\# 07-449), and H3K4me3 (Millipore Cat\# 04-745). The PCRs were done with 22 cycles for the input samples and with 30 cycles after ChIP.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.014](10.7554/eLife.06671.014)

Since TrAP is a transcriptional activator protein, we next asked whether the increased transcription of the *TrAP*-responsive protein-coding genes is associated with changes in the histone methylation status. First, we screened numerous loci that showed transcriptional deregulation in the *TrAP* overexpression lines ([Figure 2B--D,G,H](#fig2){ref-type="fig"}) for the presence of various histone modifications. We identified a dozen loci in which H3K9me2 marks are easily detected in wild-type plants. We then conducted ChIP-qPCR for these loci in the *TrAP* transgenic plants. As expected, H3K9me2 and H3K27me3 were reduced in most of the tested loci in *ddm1*, *kyp* and *lhp1* mutants, whereas H3K4me3 was enriched. These results are consistent with the generally antagonistic roles of H3K4me3 and H3K9me2 modifications. Specifically, six out of seven TrAP deregulated loci including the flowering-promoting genes displayed greater than twofold reduction in H3K9me2 and H3K27me3 in the *TrAP* overexpression plants compared to wild-type Col-0, while changes in H3K4me3 were inconsistent. This scenario was similar to that observed for TEs ([Figure 6B,C](#fig6){ref-type="fig"}). Collectively, the ChIP assays indicated that TrAP interferes with the epigenetic pathways through reducing repressive H3K9me2 marks in vivo.

TrAP decreases CHH DNA methylation {#s2-7}
----------------------------------

KYP, SUVH5, and SUVH6 are required for maintenance of non-CG (CHG and CHH) methylation in *Arabidopsis* ([@bib51]; [@bib50]). We predicted that inhibition of KYP function by TrAP might indirectly cause reduction in non-CG DNA methylation. To test this, we conducted genome-wide bisulfite sequencing with 11-day-old seedlings of TrAP transgenic plants, *kyp* mutant, and Col-0. Consistent with previous studies, *kyp* mutant showed genome wide loss of methylation in CHG (∼42.1%) and CHH (∼21.7%), but not in CG (∼2%) contexts when compared to Col-0. To our surprise, *TrAP* transgenic plants only exhibited decrease in methylation of CHH (∼11%) but not CHG ([Figure 7A](#fig7){ref-type="fig"}).10.7554/eLife.06671.015Figure 7.TrAP reduces CHH DNA methylation in vivo.(**A**) Genome-wide heatmap of DNA methylation levels in Col-0, *kyp* mutant, and *TrAP* transgenic plants (Left). Sequence context of all cytosine, CG, CHG, and CHH methylation was depicted as black, yellow, blue, and red, respectively. The percentage of cytosine methylation is shown for each genotype (Right). (**B**) Average distribution of context-specific DNA methylation in Gene- and TE-rich regions in Col-0 (red), *kyp* mutants (green), and *TrAP* transgenic plants (blue). (**C**). Overlap of CHH DMRs between *TrAP* transgenic plants and *kyp* mutant.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.015](10.7554/eLife.06671.015)10.7554/eLife.06671.016Figure 7---figure supplement 1.Gene ontology of CHH hypomethylated genes in TrAP transgenic plants and kyp mutant.The genes associated to the CHH hypomethylated DMRs in both *TrAP* transgenic and *kyp* mutant plants underwent Gene Ontology analysis using AgriGo tool with TAIR10 as reference.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.016](10.7554/eLife.06671.016)

To further analyze the effect of TrAP on DNA methylation, we identified differentially methylated regions (DMRs) by scanning the genomes in 200 bp tiles and comparing the level of methylation among *kyp* and *TrAP* overexpression plants with Col-0 ('Materials and methods') ([Supplementary files 5, 6, 7](#SD5-data SD6-data SD7-data){ref-type="supplementary-material"}). Given that non-CG methylation is highly co-localized and predominant in TE-rich heterochromatic regions ([@bib51], [@bib50]; [@bib45]; [@bib17]; [@bib58]), we separated the DMRs into gene- and TE-rich regions (GRR and TERR respectively); When compared to Col-0, *TrAP* transgenic plants displayed loss of CHH methylation at GRR but not in TERR, nor in CG or CHG contexts ([Figure 7B](#fig7){ref-type="fig"}). Remarkably, of the 3442 and 1784 GRR hypomethylated DMRs identified in *kyp* mutant and TrAP transgenic plants, 1642 were shared. To better understand the effect of *TrAP* expression on CHH DNA methylation, the GRR DRMs were further separated into promoter, terminator, UTR, intronic, and coding regions. We found that *TrAP* hypomethylated DMRs in coding sequences, UTRs, and introns overlapped almost completely with the *kyp* mutant (96.7%, 96%, and 95.4% respectively) ([Figure 7C](#fig7){ref-type="fig"}). Notably, gene ontology analysis of the overlapped genes pointed to response genes, specifically in the protein kinase category ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}; [Supplementary file 7](#SD7-data){ref-type="supplementary-material"}). This substantial overlap explains about one-third of the total CHH DMRs in *kyp* mutant, and one half of *kyp* DMRs in genic regions ([Figure 7C](#fig7){ref-type="fig"}). Together, these results suggest an inhibitory effect of TrAP in KYP-dependent CHH DNA methylation.

TrAP inhibits KYP activity to counter host defense {#s2-8}
--------------------------------------------------

In animals, H3K9 methylation promotes TGS and latency of integrated viruses. In plants, Geminivirus constitutes into a minichromosome that also undergoes epigenetic regulation. The specific TrAP-KYP interaction, inhibition of KYP activity in vitro, and reduction of H3K9me2 and CHH methylation in vivo suggest that KYP is a major factor in combating viruses. Previous studies showed that *kyp* mutants are hypersusceptible to Geminivirus infection ([@bib24]); these experiments were reproducible in our hands ([Figure 8A--D](#fig8){ref-type="fig"}). Moreover, the hypersusceptibility of *kyp* mutant to the virus could be rescued by the wild-type *KYP* transgene under the control of both the native and the constitutive 35S promoters ([Figure 8A--D](#fig8){ref-type="fig"}); further validating a role for KYP in regulation of viral infection. In line with the phenotypic complementation, wild-type *KYP* almost completely rescued H3K9me2 defects of the TEs in the *kyp* mutant ([Figure 8E](#fig8){ref-type="fig"}, lanes 1--4). Interestingly, although the accumulation of *KYP* transcripts was substantially increased when transcribed from the *35S* promoter when compared to the native promoter, the steady-state protein level was only twofold to threefold higher in the *35S-Flag-4Myc-KYP* than in the *P*~*KYP*~-*Flag-4Myc-KYP* transgenic plants (data not shown). These observations suggest a possible homoeostatic regulation of this critical TGS component.10.7554/eLife.06671.017Figure 8.KYP methylates Geminivirus chromatin as a host defense.(**A**) Western blot analysis of *kyp* complementation lines expressing *P*~*KYP*~- or *35S-Flag-4Myc-KYP* using anti-myc antibody. \*, a cross-reaction band serves as a loading control. (**B**) Representative CaLCuV symptoms with different severities. (**C**) Time course of CaLCuV symptom development in *kyp* mutant and the complementation lines. The mean values were calculated with SD from at least three experiments (\>30 plants/line). (**D**) CaLCuV symptom severity in Col-0, *kyp* mutant, and the complementation lines. The mean values were calculated with SD from at least three experiments (\>30 plants/line). (**E**) ChIP-PCR of H3K9me2 marks in heterochromatic loci in *kyp* mutant and complementation lines inoculated with mock or CaLCuV. Note: CaLCuV infection largely removed H3K9me2 marks from heterochromatic loci. (**F**) Schematic linearized representation of the regions of viral genome A selected for ChIP assays. (**G**) ChIP-qPCR assays showed KYP-dependent enrichment of H3K9me2 in several tested loci in the viral chromatin. The relative value of histone methylation in each sample was normalized to that of wild-type control where the signal was arbitrarily assigned a value of 1 with standard deviation (SD) from at least three biological repeats. Note: the region defined by \# Primer 7 serves as a negative control. (**H**) Western blot analysis to detect Flag-Myc~4~-KYP in the ChIP (IP) samples using anti-myc antibody. (**I**) ChIP-PCR assays showed that KYP binds to the viral minichromosome. The ChIP assays were done with a monoclonal anti-Flag antibody.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.017](10.7554/eLife.06671.017)10.7554/eLife.06671.018Figure 8---figure supplement 1.Virus chromatin contains H3K9me2 marks.ChIP-PCR assays of H3K9me2 marks on the CaLCuV DNA A. ChIP assays were conducted on 9-day-old seedlings using antibodies specific for H3K9me2 (Abcam Cat\# ab1220), H3K27me3 (Millipore Cat\# 07-449), and H3K4me3 (Millipore Cat\# 04-745). The PCRs were done with 22 cycles for the input samples and with 28 cycles after ChIP.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.018](10.7554/eLife.06671.018)

Geminivirus minichromosome harbors H3K9me2 ([Figure 8G](#fig8){ref-type="fig"}; [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}) ([@bib24]). Interestingly, H3K9me2 marks were dramatically decreased on several, but not all tested loci in the viral genome in *kyp* mutant, and the methylation marks were further restored by the *KYP* transgene, suggesting that viral chromatin H3K9me2 is catalyzed by KYP. Notably, the H3K9me2 amount was substantially enhanced in the locus defined by Primer \#9 in the transgenic *KYP* overexpression plants ([Figure 8G](#fig8){ref-type="fig"}). It is noteworthy that this locus harbors the promoter element for *TrAP* itself ([@bib48]). This result suggests that the tight control of *TrAP* expression likely determines the balance between the host and virus interactions. If so, the result might also explain the relatively milder viral symptoms of *35S-Flag-Myc4-KYP* lines compared to WT control or *P*~*KYP*~*-Flag-Myc4-KYP* complementation lines ([Figure 8A--D](#fig8){ref-type="fig"}). To further test whether KYP methylated the viral chromatin, we performed ChIP assays using monoclonal anti-Flag antibody to pull down *Flag-Myc*~*4*~*-KYP* bound chromatin ([Figure 8H](#fig8){ref-type="fig"}). Excitingly, KYP was found at all tested loci in the viral chromatin ([Figure 8I](#fig8){ref-type="fig"}). Notably, regions delineated by the primer \#7 showed KYP-independent H3K9me2 marks but were still immunoprecipitated in the KYP-chromatin complex. A possible explanation is incomplete chromatin shearing of the small viral mini-chromosome under the conditions used in this experiment, which were standardized for host chromatin ChIP. Alternatively, this might suggest the presence of additional epigenetic regulation that masks KYP activity on this locus. This notwithstanding, our results indicate that KYP directly deposits the H3K9me2 mark on the Geminivirus minichromosome to reinforce the silent status of the virus.

Since constitutive expression of *TrAP* reduced H3K9me2 in vivo, we wondered if Geminivirus infection could also decrease the repressive marks in the host. To this end, we tested the KYP-controlled endogenous transposons for H3K9me2 accumulation. CaLCuV-infected plants showed 60--100% H3K9me2 loss in the tested loci compared to the amount in the mock-inoculated plants ([Figure 8E](#fig8){ref-type="fig"}), this is reminiscent of the molecular phenotype of *TrAP* transgenic plants, which showed lower enrichment of H3K9me2 mark at the studied loci ([Figure 6C](#fig6){ref-type="fig"}). These results indicated that Geminivirus infection largely removed the repressive H3K9me2 marks in the transposons, and that the removal resulted at least in part from TrAP function. Given that TrAP is known to activate the expression of viral genes in the minichromosome and that endogenous transposons can serve as a proxy for viral genomes, it is conceivable that virus-encoded TrAP acts to suppress KYP in order to prevent the deposition of H3K9me2-repressive marks in the epigenome, to activate the expression of viral genes.

*kyp* mutants sustain systemic infection of CaLCuV lacking a functional *TrAP* gene {#s2-9}
-----------------------------------------------------------------------------------

Previous studies show that TrAP is required for the accumulation of the virus infective form, single-stranded (ss) DNA ([@bib25]). TrAP is indispensable for systemic infection of Begomoviruses because it activates the expression of the viral ssDNA binding proteins (nuclear shuttle protein and coat protein), which are essential for releasing the virus from the nucleus and for cell-to-cell spreading ([@bib49]). If TrAP-mediated transcriptional activation and accumulation of ssDNA result from inhibition of KYP and correspondingly heterochromatin formation, then infectivity of CaLCuV lacking TrAP should be impaired in wild-type but recovered in *kyp* plants. To test this hypothesis, we engineered a CaLCuV variant without functional TrAP protein (CaLCuV Δ*trap*) by changing a single nucleotide (T to A) that produces an amber mutation and introduces an XbaI restriction site after the sixth codon in the *TrAP* gene ([Figure 9A](#fig9){ref-type="fig"}). Then, we assessed systemic infection of CaLCuV and CaLCuV Δ*trap* on wild-type and *kyp* plants ([Figure 9B](#fig9){ref-type="fig"}). Consistent with the hypersusceptible phenotype of *kyp* mutants to CaLCuV ([Figure 8C,D](#fig8){ref-type="fig"}), these plants accumulated significantly higher titers of CaLCuV relative to wild-type control as both the replicative intermediate, open circle (OC), and the infective particle, SS DNA ([Figure 9C](#fig9){ref-type="fig"}). Consistent with previous reports, the wild-type plants did not show any symptoms of infection ([Figure 9E](#fig9){ref-type="fig"}) or systemic accumulation of CaLCuV Δ*trap*, as evidenced by Southern blot analyses and PCR ([Figure 9C](#fig9){ref-type="fig"}). Particularly, PCR amplification followed by XbaI digestion of the viral *TrAP* region in wild-type plants infected with CaLCuV Δ*trap* showed loss of the XbaI restriction site ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). Excitingly, the viral DNA was detected, in low amount but reproducibly, in *kyp* mutants. Further PCR amplification of the *TrAP* gene followed by XbaI digestion, confirmed that the detected viral DNAs in *kyp* mutants indeed came from CaLCuV Δ*trap* and not from a reversion of the mutation in the virus genome. These results show that *kyp* plants sustained systemic infection of CaLCuV Δ*trap*. Noticeably, the titers of accumulated CaLCuV Δ*trap* were much lower than the ones of CaLCuV, suggesting either redundant activity of *KYP* paralogs in host defense or necessity of additional functions of TrAP besides inhibition of KYP activity for the virus to achieve efficient infection.10.7554/eLife.06671.019Figure 9.Infectivity of CaLCuV lacking functional TrAP protein.(**A**) Sequence alignment of CaLCuV Δ*trap* and CaLCuV sequences. The translated amino acids are shown for each sequence, and the XbaI restriction site resulting from the T to A point mutation is highlighted. (**B**) Schematics of the systemic infection experiment. Plants with eight true leaves (depicted in gray) were inoculated with the begomovirus, and 18 days post inoculation nine to 11 newly emerged, not inoculated, rosetta leaves (depicted in bright green) were collected to test for virus systemic infection. (**C**) Southern blot analysis of viruses in non-inoculated leaves of infected plants. Ethidium bromide staining of total genomic DNA serves as a loading control (top panels). Southern blots were probed against CaLCuV DNA A common region (CR) (bottom panels); the viral populations are indicated as the replicative intermediate open circle (OC), linear (L), super coiled (SC) and the infective particle ss DNA. (**D**) Genotypic confirmation of the systemically amplified viruses. Top panels show PCR amplification of a *TrAP*-containing region; bottom panels show EcoRI and XbaI digestions of PCR products to examine the presence of the amber mutation in the gene. (**E**) Exemplary phenotypes of wild-type and *kyp* mutant plants inoculated with mock, CaLCuV and CaLCuV Δ*trap*. (**F**) Model of TrAP suppression of KYP activity to prevent epigenetic silencing of the viral chromatin. Geminivirus genome is packed on histone octamers to form a minichromosome. The minichromosome undergoes extensive H3K9me2 modification deposited by host-encoded KYP, and this modification could be further reinforced by DNA methylation, leading to formation of viral heterochromatin. As a counter-defense strategy, Geminivirus-encoded TrAP protein inhibits KYP activity to maintain the euchromatic status of the minichromosome to allow active replication and transcription of viral genes and correspondingly to escape host surveillance.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.019](10.7554/eLife.06671.019)10.7554/eLife.06671.020Figure 9---figure supplement 1.CaLCuV lacking functional TrAP protein cannot cause systemic infection in wild-type plants.The region corresponding to *TrAP* gene was amplified by PCR using the primers AL3_cterm_F and AL1_cterm_R ([Supplementary file 8](#SD8-data){ref-type="supplementary-material"}) from total DNA extracted from plants infected with CaLCuV or CaLCuV Δ*trap*. 5 μl of the PCR products were run, and 3 μl were used for digestion with EcoRI or XbaI to examine the presence of the amber mutation in all the amplified products.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.020](10.7554/eLife.06671.020)

Discussion {#s3}
==========

TrAP was among the first viral suppressors identified to interfere with the TGS pathway. The prevailing model is that TrAP lowers the reservoir of transferable methyl groups by targeting ADK, a key enzyme in the SAM pathway. Here, we propose a novel model in which TrAP regulates TGS by directly targeting KYP ([Figure 9F](#fig9){ref-type="fig"}). Several pieces of evidence supported our notion: (1) TrAP genetically interfered with the TGS pathway ([Figure 2](#fig2){ref-type="fig"}); (2) TrAP directly interacted with KYP in vivo and also with other HMTase*s* in vitro ([Figure 3](#fig3){ref-type="fig"}; [Figure 4](#fig4){ref-type="fig"}); (3) TrAP inhibited the catalytic activity of KYP in vitro ([Figure 5](#fig5){ref-type="fig"}); (4) TrAP reduced the repressive H3K9me2 marks in vivo ([Figure 6](#fig6){ref-type="fig"}), and correspondingly, reactivated numerous loci that are otherwise repressed by KYP ([Figure 2](#fig2){ref-type="fig"}); (5) TrAP decreased CHH methylation in gene-rich regions that are also regulated by KYP ([Figure 7](#fig7){ref-type="fig"}); (6) methylation of viral chromatin entailed KYP ([Figure 8](#fig8){ref-type="fig"}); (7) KYP bound the viral chromatin ([Figure 8](#fig8){ref-type="fig"}); and (8) *kyp* mutants but not wild-type plants sustain low systemic infection of CaLCuV lacking TrAP protein ([Figure 9](#fig9){ref-type="fig"}). To our best understanding, this is the first evidence that a viral protein directly suppresses HMTases in the host TGS machinery.

Given that TrAP protein could concurrently limit the upstream supply of the methyl groups and directly inhibit downstream enzymatic activity of KYP, Geminiviruses appear to have evolved sophisticated strategies to cripple the host TGS pathway. What would be the biological advantages of blocking the TGS pathways? In eukaryotes, chromatin appears to be a critical battleground for virus--host interaction. Animals use histone modifications to reinforce the latency of integrated viruses ([@bib13]; [@bib38]; [@bib39]). Plant DNA viruses including Geminiviruses and pararetroviruses replicate as nuclear minichromosomes or episomes. Clearly, TGS functions as an immune system to control virus replication and the expression of viral genes, in a similar fashion as the repression of endogenous TEs and transposon remnants. In previous studies and here in our experiments, *kyp* mutants displayed hypersusceptibility to Geminivirus infection, which could be rescued by exogenous wild-type *KYP* gene. KYP directly acts on viral chromatin and deposits the repressive H3K9me2 mark on the viral chromatin. Moreover, viruses lacking the essential TrAP protein can, although inefficiently, cause systemic infection in *KYP*-deficient hosts. All these facts point out the unambiguous role of KYP-mediated TGS in defense against viral infection. On the other hand, TrAP functions to inhibit KYP catalytic activity, reducing the repressive H3K9me2 mark, to activate transcription of viral genes. Our KYP reconstitution assays show that TrAP:KYP molar ratio of around 2 is enough to cause ∼50% inhibition of KYP activity, indicating that TrAP is a potent inhibitor of HMTase activity. Thus, direct inhibition of KYP represents a novel counter-defense mechanism for virus survival in the hosts. This mechanism could account for the long-documented essential role of TrAP in expression of viral genes including the coat protein and the nuclear shuttle protein ([@bib49]; [@bib59]; [@bib46]; [@bib24]).

In plants, H3K9me2 marks often correlate with non-CG DNA methylation, and in particular with CHG modification. The tight coordination results from a self-enforcing loop consisting of KYP and CMT3 ([@bib14]). Briefly, KYP methylates H3K9 to generate the binding sites for CMT3, which further methylates CHG DNA to create more binding sites for KYP. Consequently, the crosstalk between DNA and histone methylation ascertains the silent status of heterochromatin. We hypothesized that TrAP targets KYP to reduce H3K9me2 marks, and this inhibition would further decrease DNA methylation both on the host and on the viral genome. Here, we found that ectopic expression of TrAP had no effect on CHG but only on CHH methylation, at sites that are up to 96.7% overlapped with the hypo-methylated regions in *kyp* mutant ([Figure 7C](#fig7){ref-type="fig"}). In plants, sequence contexts of CHG and CHH methylation are largely overlapped throughout the genome and are maintained to a limited extent by all non-CG methyltransferases ([@bib50]). One outstanding question would be how could TrAP differentially alter methylation of CHH rather than CHG, given that TrAP targets KYP? Methylation in the CHH context is catalyzed by CMT2 and DRM1/2 in *Arabidopsis*, and the sites regulated through the two sets of enzymes are mostly non-overlapping. Thus, the functions of CMT2 and DRM1/2 are mostly non-redundant at CHH sites ([@bib51], [@bib50]). DRM1/2 largely catalyze CHH methylation at the TE-rich regions ([@bib50]). In our study, we did not observe any effect of TrAP on CHH methylation in the TEs, suggesting that TrAP might not (or not sufficiently) interrupt the RdDM pathway that entails DRM1/2 and 24-nt siRNAs ([@bib50]). Importantly, it has been recently discovered that bulk CHH methylation is maintained by CMT2 ([@bib45]; [@bib50]; [@bib17]) and that its activity is largely dependent on H3K9me2. In this scenario, CMT2 recognizes methylated H3K9 but preferentially binds to di-methylated over mono-methylated histone tails. This preference towards H3K9me2 is not observed in the CHG methyltransferase CMT3, which can equally bind to all forms of H3K9 methylation ([@bib50]). We envision that methylation at CHH sites could be more sensitive to changes in H3K9me2 than CHG, since CMT3 could still maintain CHG DNA methylation in the presence of H3K9me1 resulting from residual activity of HMTase, as would be the case when KYP is inhibited by TrAP. Alternatively, CHH methylation might play an important but yet unappreciated regulatory role in host defense genes ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). If so, preferentially targeting these loci by TrAP protein might represent a new counter-defense mechanism.

In the host, Geminivirus DNAs also undergo extensive methylation modification ([@bib42]). In our study, TrAP reduces CHH methylation in the host and possibly in the viral genome, too. Remarkably, the Geminivirus replicase, Rep/AC1/C1 and the embedded protein AC4/C4, downregulate the expression of host DNA methyltransferases *MET1* and *CMT3* ([@bib40]; [@bib44]); hence, it interrupts the reinforcing loop of histone and DNA methylation. Consistent to this study, *cmt3* mutants exhibit hypersusceptibility to viral infection ([@bib42]). The fact that Rep/C4 repress *CMT3* expression in the host is in perfect alignment with our ChIP assay results on CaLCuV-infected plants, where the loss of H3K9me2 is even more severe than the observed in TrAP transgenic plants. Thus, interruption of the compelling feedback loop of histone and DNA methylation represents an important strategy to sustain transcription of viral chromatin. Together, it seems that the synergistic inhibition of histone and DNA methyltransferases by Geminivirus proteins evolves as a powerful tactic to win the arms race between host and pathogen.

Our in vitro assays clearly demonstrated that TrAP predominantly binds to the catalytic domain of KYP and inhibited its enzymatic activity. Whether TrAP might alter KYP conformation or block the accessibility of substrates to the active sites upon interaction awaits future structural analysis. We note, however, that *Arabidopsis* has 49 SET domain containing proteins of which 31 are considered to have HMTase activity ([@bib31]). Arising from this fact is whether TrAP specifically targets KYP or promiscuously acts on additional HMTases. Although TrAP overexpression plants display molecular features in common with *kyp* mutant (i.e., reduced H3K9me2 levels), and an early flowering phenotype similar to loss-of-function mutant of the *kyp* paralog, *SUVH2*, the transgenic plants are phenotypically different from *kyp* single mutant. This could be due to functional redundancy between *KYP* and its paralogs in vivo; alas, the morphological phenotype of the higher-order mutants has not been fully documented.

We also noticed that *TrAP*-overexpression plants are morphologically similar to *lhp1,* which is characteristic of the H3K27me3 pathway. Moreover, the substantial overlapping of *TrAP*-responsive genes with *lhp1*-regulated genes strongly suggested that TrAP might target the *LHP1*-related H3K27me3 pathway ([@bib66]). Indeed, most of our tested loci in the host genome exhibited decreased H3K27me3 levels, consistent with the fact that ∼50% genes were co-regulated by TrAP and *LHP1* in a genome-wide scale. Interestingly, recent ChIP--chip studies revealed that H3K27me3 and *LHP1*-bound sites are predominantly distributed in the euchromatic regions ([@bib53]; [@bib60], [@bib62]). This distribution is not correlated with KYP-dependent H3K9me2 marks that are highly enriched at pericentromeric regions as large and uninterrupted heterochromatic blocks ([@bib31]; [@bib5]; [@bib14]; [@bib32]). H3K9me2 can also occur in euchromatic regions but rather exist as small heterochromatin patches ([@bib66]). In our current study, we did not further examine whether TrAP physically targets H3K27me3 HMTases in the *LHP1* pathway. But it is plausible that TrAP inhibits both KYP and *LHP1* pathways. Notably, we did not observe the repression of transcriptionally active histone methylation marks, such as H3K4me3 and H3K36me3. This observation suggests that TrAP does not target the HMTases that are writers for the active marks. How can TrAP distinguish KYP from those active writers remains unclear, but we propose that structural components other than the SET domain might contribute to the recognition and affinity of TrAP binding to HMTases ([Figure 4](#fig4){ref-type="fig"}). Alternatively, additional cellular factors might also contribute to the specificity.

The direct consequence of TrAP-dependent inhibition of KYP activity is to activate viral transcription and replication. Because KYP is a key effector of TGS in the host and regulates a broad array of endogenous genes, interference with this core component would reprogram the expression profile of the host genome and thus trigger a series of downstream cascade signaling events that impact the balance of host/virus interaction. As an example, TrAP suppresses auxin and cell growth, whether this change might constitute a defense mechanism for the host benefit or create a favorable cellular niche for virus propagation remains for further investigation.

In conclusion, our results support the notion that Geminivirus-encoded TrAP protein interferes with the TGS pathway and abrogates epigenetic silencing by direct interaction with KYP and inhibition of its transmethylation activity. Thus, Geminvirus TrAP functions clearly different from most of previously characterized viral suppressors, which target various steps of the PTGS pathway ([@bib12]). Together with previous studies ([@bib42]), we provide evidence that KYP evolves as a critical immune system to control invading nucleic acids in plants; this is reminiscent of the roles of human SUV39H1 in maintaining the latency of HIV ([@bib13]), Epsteinn-Barr virus (Imai et al., 2014), and some other mammalian viruses. Thus, sequestering or interfering with this core component is an effective strategy for Geminivirus to block TGS and to subvert host defense; we expect this strategy to be used by other suppressors in plants and mammals. Given that many viral suppressors interrupt different steps in the PTGS pathways to efficiently combat host surveillance, it would not be surprising that additional key cellular factors in the TGS pathway, besides HMTase, were readily targeted by invading viruses in eukaryotes. Importantly, it is believed that compounds or drugs that alter chromatin methylation might ultimately be the most effective means of combating disease. Our discovery that TrAP inhibits a histone-modifying enzyme also offers a new natural strategy to develop epigenetic-targeted drugs to cure human diseases that arise from epigenetic dysfunction ([@bib25a]) or to engineer new biotechnological products to improve agricultural productivity.

Materials and methods {#s4}
=====================

DNA constructions {#s4-1}
-----------------

All the plant constructs were made using the Gateway system (Invitrogen, Carlsbad, CA, United States) ([@bib61]). The destination vectors (containing the destination cassette--DC-) pHyg-DC-CFP, pBA-DC-CFP, pBA-DC-3HA, pBA-DC, pBA-Flag-4Myc-DC, and pER10-YFP-DC ([@bib64]) were used for transient expression in *N. benthamiana* and for stable *Arabidopsis thaliana* transformation. The vector pER10 for betaestradiol-inducible expression under the XVE promoter ([@bib68]) was modified to obtain the destination vector pER10cLUC-3HA-DC. For this, the pER10 vector was linearized with XhoI, filled in with Klenow fragment; and further digested with PacI. In parallel, the cLuc-3HA-DC insert was obtained by linearizing the pCambia1300-cLuc-3HA-DC ([@bib65]) plasmid treated with SacI/Klenow treatment and further digested with PacI. The vector and insert were ligated and transformed into *E. coli* DB3.1 and finally confirmed by sequencing. This vector was used together with pCambia Myc-DC-nLUC ([@bib65]) for transient expression in *N. benthamiana*.

The cDNA or DNA fragments were cloned into pENTR/D vectors, confirmed by sequencing, and then transferred to the appropriate destination vectors by recombination using the LR Clonase (Invitrogen). The primers for the cloning are listed in the [Supplementary file 8](#SD8-data){ref-type="supplementary-material"}. To drive KYP expression from its native promoter, we amplified a 2.7-Kb genomic region immediately upstream of the *KYP* start codon with the primers P~KYP~ EcoRV for and P~KYP~ BamHI rev. The binary vector pBA002a Flag-4Myc-KYP was obtained by the Gateway system using LR clonase. The resultant plasmid and PCR product harboring *KYP* promoter were digested with EcoRV/BamHI and ligated with T4 DNA ligase. The plasmid was confirmed by sequencing using the primer P~KYP~ seq For.

For expression of recombinant proteins, the cDNA or DNA fragments were cloned into pMCSG9 or pMCSG10 vectors to produce His-MBP- or His-GST-tagged proteins respectively, by ligation independent cloning ([@bib18]) using primers that include 18 nt identical to the ends of the linearized pMCSG vector ([Supplementary file 8](#SD8-data){ref-type="supplementary-material"}). The pMCSG plasmids were linearized with the blunt end restriction enzyme SspI, and the sticky ends were generated by T4 DNA Polymerase (NEB, Ipswich, MA, United States) supplemented with 2.5 mM dGTP. In parallel, the complementary sticky ends in the PCR products were generated supplementing the T4 DNA Polymerase (NEB) with 2.5 mM dCTP. The mixture of treated plasmid:PCR (3:4, respectively) was incubated on ice for 30 min to allow annealing of the complementary free strands and transformed in *E. coli* DH5α. The plasmids were further confirmed by sequencing and transformed into *E. coli* BL21 Rossetta DE3 for expression.

To engineer the CaLCuV Δ*trap* DNA A infective clone the pNSB1090 plasmid was subjected to site directed mutagenesis by amplification with the primers CaLCuV_AL2_null_XbaI_for and CaLCuV_AL2_null_XbaI_rev ([Supplementary file 8](#SD8-data){ref-type="supplementary-material"}), digested overnight with DpnI, cleaned with the QIAquick PCR Purification Kit (Qiagen, Germantown, MD, United States), and amplified in *E. coli* DH5α. The plasmid was confirmed by sequencing and transformed in *Agrobacterium tumefasciens* ABI for the virus infection assays.

Transgenic plants {#s4-2}
-----------------

*A. thaliana* (Col-0) plants were transformed with binary vectors by the floral-dip method ([@bib9]; [@bib63]). The transgenic seeds were selected on standard MS medium ([@bib36]) containing the appropriate selective agents: 10 mg/l glufosinate ammonium (Sigma-Aldrich, St. Louis, MO, United States) or 25 mg/l hygromycin (Sigma), together with 100 mg/l carbenicillin (Sigma). *kyp* mutant (SALK_130630C) was obtained from the Arabidopsis Biological Resource Center (ABRC) and confirmed by genotyping and qRT-PCR.

Expression and purification of recombinant proteins {#s4-3}
---------------------------------------------------

For in vitro pull-down or HMTase reconstitution assays, the recombinant proteins were purified following either one or two-step affinity purification procedure. His-MBP-tagged proteins were first purified through Immobilized Metal Affinity Chromatography (IMAC) using the Ni-NTA resin (Qiagen), followed by amylose resin (NEB) according to manufacturers\' protocols. His-GST-tagged proteins were initially purified through sepharose glutathione column (GE Healthcare, United Kingdom) followed by IMAC. Specifically for HMTase assays, His-MBP-CaLCuV_TrAP, His-MBP-TGMV_TrAP, and His-MBP were prepared in lysis buffer (50 mM Tris-HCl pH 9, 300 mM NaCl, 10 mM 2-mercaptoethanol, 2 mM PMSF), incubated with the Ni-NTA resin at 4°C for 1 hr, eluted with 300 mM imidazole and immediately incubated with the amylose resin (NEB) at 4°C for 1 hr. The proteins were eluted with 10 mM maltose and the elute was further separated by size exclusion chromatography (SEC) in column buffer (20 mM Tris-HCl pH 9, 100 mM NaCl); the fractions containing the target protein were pulled together, concentrated to 100 µM, aliquoted and stored at −80°C until usage. His-GST-KYP was prepared in PBS buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na~2~HPO~4~, 1.8 mM KH~2~HPO~4~, pH 7.3, 10 mM 2-mercaptoethanol) incubated with the sepharose glutathione 1 hr at 4°C, eluted with elution buffer (50 mM Tris-HCl pH 9, 200 mM NaCl, 10 mM reduced glutathione, 10 mM 2-mercaptoethanol). The elute was further purified through the Ni-NTA column and finally through SEC in column buffer (20 mM Tris-HCl pH 9, 100 mM NaCl); the fractions containing the target protein were pulled together, concentrated to 25 μM and aliquoted for usage.

For in vitro pull down assay, both the prey (His-GST-CaLCuV-TrAP, His-GST-TGMV-TrAP, and His-GST) and the bait (His-MBP-Bait) proteins were purified by IMAC using the lysis buffer (50 mM Tris-HCl pH 8, 300 mM NaCl, 20 mM imidazole, 2 mM PMSF), incubated with the Ni-NTA resin at 4°C for 1 hr, eluted with 300 mM imidazole and immediately dialyzed in storage buffer (20 mM Tris-HCl pH 8, 150 mM NaCl, 2 mM 2-mercaptoethanol, 50% Glycerol) at 4°C overnight.

In vitro pull down and Co-IP assays {#s4-4}
-----------------------------------

In vitro pull-down assays and in vivo Co-IP were done as described ([@bib61]). Briefly, 2.5 μg of 6His-GST-tagged prey proteins were pre-absorbed to 50 µl of the amylose resin (NEB) for 1 hr at 4°C in 1 ml of binding buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.2% glycerol, 0.6% Triton X-100, 0.5 mM 2-mercaptoethanol, 2 mM PMSF). The proteins were recovered by ultracentrifugation at 12,000×*g* for 2 min, transferred to a second tube containing 2.5 µg of the MBP-tagged bait protein, and incubated at room temperature for 2 hr. The protein complexes were harvested by adding 50 µl amylose resin beads, followed by 2 hr incubation at room temperature, and cleaned with six vigorous washes with buffer. The pulled-down proteins were resolved by SDS-PAGE and the preys were detected by western blot using anti-GST antibody.

For Co-IP experiments, *N. benthamiana* leaves were collected 2 days after agroinfiltration, ground in liquid nitrogen and stored at −80°C until use. For the assay, total proteins were extracted from 0.4 g of ground powder in 1.2 ml (3 vol) of IP buffer (40 mM Tris-HCl pH 7.5, 300 mM NaCl, 5 mM MgCl~2~, 2 mM EDTA, 4 mM DTT, 0.5% Triton X-100, 1 mM PMSF, 5% glycerol, 1 pellet/25 ml Complete EDTA-free protease inhibitor \[Roche, Indianapolis, IN, United States\]); then, the soluble proteins were cleared twice by ultracentrifugation at 20,000 × rcf for 15 min at 4°C. The protein complexes were immunoprecipitated with 15 µl Anti-c-Myc-agarose affinity gel (Sigma--Aldrich \#A7470) at 4°C for 2 hr, the unspecific-bound proteins were removed by four consecutive washes with the IP buffer with 10 min incubation each at 4°C. The protein complexes were eluted in 200 μl of elution buffer (5 mM EDTA, 200 mM NH~4~OH) for 20 min. The supernatant was collected, frozen in liquid nitrogen and dried using the Savant SpeedVac concentrator; finally, the sample was solubilized in 50 μl of 2× SDS-loading buffer for western blot analyses.

Two-step immunoprecipitation for mass spectrometry analysis {#s4-5}
-----------------------------------------------------------

9-day-old wild-type control and *Arabidopsis* transgenic plants expressing *XVE-Flag-Myc4-TrAP* were induced for 16 hr with 25 µM ß-estradiol in liquid MS media, ground in liquid nitrogen and stored at −80°C until use. For the assay, total proteins were extracted from 10 g of ground powder in 40 ml (4 vol) of IP buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM MgCl~2~, 50 μM ZnCl~2~, 0.1% Triton X-100, 1 mM PMSF, 1% glycerol, 1 pellet/17 ml Complete EDTA-free protease inhibitor \[Roche\], 15 μM MG132); then, the soluble proteins were cleared twice by ultracentrifugation at 20,000 × rcf for 15 min at 4°C. The protein complexes were first immunoprecipitated using 500 μl of Anti-FLAG M2 magnetic beads (Sigma-Aldrich, Cat\# M8823) and incubated in slow rotation for 2 hr at 4°C, the nonspecific-bound proteins were removed by three consecutive washes with 15 ml of IP buffer for 10 min incubation each at 4°C. The protein complexes were then eluted by competition with 100 mg/ml FLAG peptide and subsequently immunoprecipitated with 100 µl Anti-c-Myc-agarose affinity gel (Sigma--Aldrich \#A7470) at 4°C for 1.5 hr, the nonspecific-bound proteins were removed by five consecutive washes with the IP buffer with 5 min incubation each at 4°C. The protein complexes were eluted in 200 μl of elution buffer (5 mM EDTA, 200 mM NH~4~OH) for 20 min. The supernatant was collected, frozen in liquid nitrogen and dried using the Savant SpeedVac concentrator; finally, the sample was solubilized in 30 μl of 2× SDS-loading buffer and run in 10% SDS-PAGE. The samples were run to one-third of the gel, stained with Coomassie blue and collected by excising the whole lane for mass spectrometry analysis in the Taplin Mass Spectrometry Facility at Harvard Medical School.

Southern blot analyses {#s4-6}
----------------------

The plant material was lysed in CTAB buffer (100 mM Tris HCl pH 8.0, 20 mM EDTA pH 8.0, 1.4 M NaCl, 2% CTAB, 2% ß-mercaptoethanol); then total DNA was extracted with phenol:chlorophorm:isoamyl alcohol (25:24:1) and precipitated with 2-propanol. The DNA was treated with RNase A and further purified with phenol:chlorophorm:isoamyl alcohol (25:24:1) and precipitated with ethanol, then dissolved in ultrapure water. The specified amount of DNA was separated by electrophoresis in 0.8% agarose, transferred overnight by capillarity to a Hybond-N membrane (GE Healthcare), and probed with ^32^P-labeled probe targeting the CR region of CaLCuV DNA A. The probe was obtained by PCR using the primers CR_F and CR_R ([Supplementary file 8](#SD8-data){ref-type="supplementary-material"}) and labeled using the Rediprime II DNA Labeling System (GE Healthcare) following the manufacturer\'s instructions.

RNA blot analyses {#s4-7}
-----------------

Total RNA was extracted using Trizol reagent from either adult rosette leaves or 2-week-old seedlings of independent transgenic lines, the RNA blots were then performed as previously described ([@bib64]).

Immunoprecipitation of Flag-AGO1-associated small RNAs {#s4-8}
------------------------------------------------------

Immunoprecipitation of Flag-AGO1-associated small RNAs were performed as described ([@bib64]). RNA was recovered with Trizol reagent from the immunoprecipitates, separated in 8 M urea, 15% polyacrylamide gels and subjected to RNA blot analysis of low-molecular-weight RNAs.

Luciferase complementation imaging (LCI) assay {#s4-9}
----------------------------------------------

The LCI was performed on 4-week-old *N. benthamiana* leaves infiltrated with various combinations of *A. tumefaciens* GV3101 harboring pCambia Myc-TrAP-nLUC or pCambia Myc-nLUC and *A. tumefaciens* ABI carrying pER10cLUC-3HA or pER10cLUC-3HA-candidate proteins. The agrobacteria containing the pER10 plasmids were incubated with 25 µM beta-estradiol for 3 hr prior infiltration, and all the cultures were adjusted to OD~600~ = 0.8. The transfected leaves were assayed 2 days after agroinfiltration by adding the substrate (10 mM luciferin). The sprayed leaves were incubated in total darkness for 5 min and photographed using an electronmultiplying charge-coupled device (EMCCD) camera, Cascade II 512, from Photomerics (Roper Scientific, Trenton, NJ, United States). The images were processed with WinView32 Ver 2.5.19.7 (Roper Scientific).

Confocal microscopy and FRET assays {#s4-10}
-----------------------------------

Leaves of 4-week-old tobacco plants (*N. benthamiana*) were agroinfiltrated with syringe without needle as previously described ([@bib61]) with *A. tumefasciens* ABI carrying pBA-TrAP-CFP and pER10-YFP-Test protein. The agrobacteria containing the pER10 plasmids were incubated with 25 µM beta-estradiol for 3 hr prior infiltration, and all the cultures were adjusted to OD~600~ = 0.8. The plants were maintained for 2 days at 24°C (16 hr light/8 hr dark). The co-localization was evaluated using a Nikon inverted microscope Eclipse T*i*-E (Nikon, Japan). CFP signal was measured by excitation with Shutter 10-3 filter 3 (CFPHQ \[Ex\]), and emission was detected at 485 nm; YFP used Shutter 10-3 filter 4 (YFPHQ \[Ex\]) and emission was detected at 540 nm. The images were processed using NIS-Elements-AR 4.30.01 (Nikon) and Adobe Photoshop software.

FRET-AB experiments were performed on *N. benthamiana* epidermal cells of 4-week-old leaves agroinfiltrated with a 1:1 mixture of pBA-TrAP-CFP and pER10-YFP-KYP to a final OD~600~ = 0.8. YFP and CFP signals were captured with a Zeiss LSM 710 confocal Microscope (Zeiss, Germany). FRET was determined by the acceptor photobleaching method ([@bib26]; [@bib10]). First, to define the base line, the signal intensities of a pre-photobleach CFP (donor) and YFP (acceptor) were acquired by exciting with the 458 and 514-nm laser lines, respectively. Then, three regions of interest in the cell were selected: \#1, Autofluorescence control; \#2, non-photobleaching control; and \#3, FRET-AB region. The CFP donor was excited with the 458 nm laser line for all FRET experiments; the emission of both CFP and YFP was recorded at 485 nm and 540 nm. Regions \#1 and \#3 were rendered free of YFP by consecutive cycles of bleaching recovery with the 514-nm laser line until no recovery of YFP was detected. The CFP and YFP signals were monitored throughout the experiment. After correction for background with control region \#1 and for photobleaching of the donor because of imaging with control region \#2, the FRET efficiencies (E) in the region \#3 was calculated from the CFP signal using $\text{FRET}_{\text{Eff}} = 1 - \frac{\text{D}_{\text{pre}}}{\text{D}_{\text{post}}}$, where D is the mean intensity of the donor CFP in the area where the acceptor was bleached, before (Dpre) and after (Dpost) acceptor bleaching. The FRET efficiency is considered positive when Dpost \> Dpre. The image and statistical analyses were performed with the FRET module for the ZEN software (Zeiss). The average FRET efficiency and its standard deviation were calculated from the FRET efficiencies of each individual cell in 27--30 cells per experiment. The standard Student\'s *t*-test was used to determine the statistical significance of the results.

HMTase reconstitution assay {#s4-11}
---------------------------

In vitro HMTase reactions were modified from ([@bib43]; [@bib52]) as follows: 20 µl of reaction mixture containing 3.3 µM Histone 3.2 (NEB), 1 µM His-GST-KYP, and 50 nCi of S-adenosyl-\[methyl-^14^C\]-L-methionine in HMTase buffer (50 mM Tris-HCl pH 9, 10 mM MgCl~2~, 1 mM ß-mercaptoethanol, 250 mM sucrose) was incubated for 0--10 min at 37°C. The reaction products were separated by 18% SDS-polyacrylamide gel electrophoresis and visualized by Coomassie Brilliant Blue R-250 staining; then, the gels were fixed 1 hr in fixing solution (25% Ethanol, 2% Glycerol) and scintillated for 30 min in 1 M sodium salicylate. Gels were dried 2 hr at 80°C. The ^14^C signal was detected by fluorography using in a preflashed Classic autoradiography film blue sensitive; Filters Kodak Wratten No. 22 and No. 96 were used together for preflashing. Preflashed film was exposed 5--7 days at −80°C. The film was developed using a Kodak M35A X-OMAT Processor, and the results were digitalized in a Chemi-Doc XRS System and analyzed with the Image Lab Software (Bio-Rad, Hercules, CA, United States).

To assess the impact of TrAP on KYP activity, His-MBP-TrAP or His-MBP were pre-incubated with His-GST-KYP in different molar ratios, ranging from 0 to 10, for 1 hr at room temperature, then the assays were proceeded as described above. The experiments were performed 3--5 times for statistical analysis.

ChIP assays {#s4-12}
-----------

The analysis of histone modifications was performed as described ([@bib44a]). Two grams of 9-day-old seedlings were crosslinked with 1% formaldehyde for 10 min by vacuum infiltration at 4°C; the reaction was stopped with 2 M Glycine to a final concentration of 100 mM at room temperature. Plants were rinsed 5 times with ice cold with water, flash-frozen in liquid nitrogen, and ground with mortar and pestle. The powder was suspended in 6 vol (12 ml) of nuclei isolation buffer (15 mM PIPES-KOH pH 6.8, 0.25 M sucrose, 0.9% Triton X-200, 5 mM MgCl~2~, 60 mM KCl, 15 mM NaCl, 1 mM CaCl~2~, 1 mM PMSF, 1 pellet/50 ml Complete EDTA-free Protease inhibitor \[Roche\]), filtered through two layers of Miracloth and centrifuged at 11,000 × rcf for 10 min in 4°C. After discarding the supernatant, the pellet was resuspended in 1 ml of Nuclei lysis buffer (50 mM HEPES pH 7.5, 1 mM EDTA pH 8.0, 150 mM NaCl, 1% SDS, 0.1% Sodium Deoxycholate, 1% Triton X-100, 1 pellet/50 ml Complete EDTA-free Protease inhibitor \[Roche\]); the samples were sonicated in 10 cycles 30 s ON and 90 s OFF, using the Bioruptor (Diagenode, Belgium) at the highest power in 4°Cs. The sonicated samples were centrifuged for 10 min at 21,000 × rcf in 4°C. 100 μl of the clarified chromatin was diluted 10-fold with Nuclei lysis buffer without SDS for each assay. The immunoprecipitation was accomplished by the addition of 40 µl Protein A Dynabeads (Invitrogen) and 3 μl of the pertinent antibody, followed by 6 hr incubation at 4°C on mild rotation. The beads-conjugated complexes were washed with 1 ml of Low salt buffer (20 mM Tris-HCl pH 8.0, 2 mM EDTA pH 8.0, 150 mM NaCl, 0.5% Triton X-100, 0.2% SDS), followed by 1 ml of high salt buffer (20 mM Tris-HCl pH 8.0, 2 mM EDTA pH 8.0, 500 mM NaCl, 0.5% Triton X-100, 0.2% SDS), then with 1 ml of LiCl buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 250 mM LiCl, 1% sodium deoxycholate, 1% NP-40), and finally twice with 1 ml of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) by incubating 5 min at 4°C in between washes. The samples were eluted twice at room temperature with 250 μl of elution buffer (100 mM NaHCO~3~, 0.5% SDS), for 15 and 30 min, respectively. The samples were decrosslinked with 100 mM NaCl at 65°C overnight, followed by Proteinase K treatment for 90 min at 45°C. The DNA was purified by Phenol:Chloroform:IsoamylAlcohol 25:24:1, and precipitated in 100% Ethanol at −80°C.

The antibodies used are mono-clonal anti-H3K9me2 (Abcam, \#Ab1220); monoclonal anti-H3K4me3 (Millipore, cat \#04-745); mono-clonal anti-H3K27me3 (Millipore, cat \#07-449).

The immunoprecipitation of Flag-4Myc-KYP-Chromatin complexes was done as in ([@bib56a]), using Anti-FLAG M2 magnetic beads (Sigma-Aldrich, Cat\# M8823). Two grams of rosette leaves 1--12 of mock or CaLCuV inoculated plants at 18 dpi were crosslinked with 1% formaldehyde for 25 min by vacuum infiltration at 4°C; the reaction was stopped with 2 M Glycine to a final concentration of 100 mM. Plants were rinsed five times with ice cold with water, flash-frozen in liquid nitrogen, and ground with mortar and pestle. The powder was suspended in 5 vol (10 ml) of Honda Buffer (20 mM HEPES-KOH pH 7.4, 0.44 M sucrose, 1.25% ficoll, 2.5% Dextran T40, 10 mM MgCl~2~, 0.5% Triton X-100, 5 mM DTT, 2 mM PMSF, 1 pellet/25 ml Complete EDTA-free Protease inhibitor \[Roche\]), filtered through two layers of Miracloth and centrifuged at 2000 × rcf for 15 min in 4°C. After discarding the supernatant, the nuclear precipitates were washed three times with 1 ml of Honda buffer; subsequently, the pellet was suspended in 300 μl of Nuclei lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 1% SDS, 2 mM PMSF, 1 pellet/25 ml Complete EDTA-free Protease inhibitor \[Roche\]) and sonicated in ten cycles 30 s ON and 90 s OFF, using the Bioruptor (Diagenode) at the highest power in 4°Cs. The sonicated samples were centrifuged for 10 min at 21000 × rcf in 4°C. 100 μl of the clarified chromatin was diluted 10-fold with ChIP dilution buffer (16.7 mM Tris-HCl pH 8.0, 1.2 mM EDTA pH 8.0, 167 mM NaCl, 1.1% Triton X-100, 1 pellet/25 ml Complete EDTA-free Protease inhibitor \[Roche\]) per ChIP. The immunoprecipitation was accomplished by the addition of 40 µl of Anti-FLAG M2 magnetic beads (Sigma-Aldrich, Cat\# M8823), followed by 2 hr incubation at 4°C on mild rotation. The beads were washed five times with 1 ml of Washing buffer (20 mM Tris-HCl pH 8.0, 2 mM EDTA pH 8.0, 150 mM NaCl, 1% Triton X-100, 1% SDS, 2 mM PMSF, 1 pellet/25 ml Complete EDTA-free Protease inhibitor \[Roche\]) incubating 5 min at 4°C in between; then, two more washes with 1 ml TE buffer incubating 5 min at 4°C. Finally, the samples were eluted twice at room temperature with 125 μl of Elution buffer (100 mM NaHCO~3~, 0.5% SDS), for 15 and 30 min, respectively. The samples were decrosslinked and the DNA extracted as above.

Microarray analysis {#s4-13}
-------------------

Microarray analyses using the Affymetrix ATH1 platform were performed with two biological replicates using wild-type plants, *35S-TrAP* transgenic plants, and *lhp1* mutants. Seedlings were grown on MS medium with 1% sucrose for 7 days. One mg of total RNA was used for reverse transcription using MessageAmp II aRNA kits (Ambion) and 15 mg of labeled cRNA for hybridization. GeneChip hybridization and scanning were performed at the Genomics Resource Center, Rockefeller University, New York.

Statistical analysis of microarray data was performed using R software. Initially the microarray plates were tested for quality by an M plot and the data normalized by the RMA method from the Affy package. Subsequently, the distribution of the samples was assessed with scatter plots and the normalized data sets were evaluated with the Moderate t-test from R package limma for p-value computation. Then, the eBays method was used to compute moderated t-statistics and log-odds of differential expression by empirical Bayes shrinkage of the standard errors towards a common value. The moderated t-statistic (t) is the logFC to its standard error. In our DEG results our thresholds are p-value \< 0.05 and logFC \>1 (up-regulated) or logFC \< −1 (down-regulated). The False Discovery Rate was approximated from the eBayes adjusted p-value.

The significance of the overlapping data sets was calculated through Pearson\'s Chi-squared test with 1° of freedom.

Quantitative PCR and RT-PCR {#s4-14}
---------------------------

Expression levels of the tested genes were examined by quantitative RT-PCR. Total RNAs were prepared from 9 days-old seedlings and treated with DNase before being subjected to cDNA synthesis using Superscript III reverse transcriptase (Invitrogen) primed by random primers. The EF1a gene ([@bib57]) was included as an internal control for normalization. The enrichment levels of specific genes after ChIP assay were also tested by quantitative PCR. Primers are listed in [Supplementary file 8](#SD8-data){ref-type="supplementary-material"}. The quantitative PCRs were performed in 384-well plates with an ABI7900HT real-time PCR system using the SYBR Green I master mix (Applied Biosystems, Waltham, MA, United States) in a volume of 10 μl. PCR conditions were as follows: 50°C for 2 min, 95°C for 10 min, 45 cycles of 96°C for 10 s followed by 60°C for 1 min. Three biological repeats were performed, and the reactions were performed in triplicate for each run. The comparative CT method was used to evaluate the relative quantities of each amplified product in the samples. The threshold cycle (CT) was automatically determined for each reaction by the system according to the default parameters. The specificity of the PCR was determined by dissociation curve analysis of the amplified products using the standard method installed in the system.

Whole genome bisulfite sequencing {#s4-15}
---------------------------------

Approximately 500 ng of genomic DNA were used to generate libraries as described ([@bib21]) using premethylated adapters (NEXTFlex Bisulfite-Seq Adapters \#511911, Bioo Scientific, Austin, TX, United States). The adaptor-ligated fragments were purified by QIAQuick column (Qiagen) and bisulfite converted using the EpiTect Kit (Qiagen, Germany) following the manufacturer\'s instructions. The converted DNA was later enriched by 15 cycles of PCR using the Pfu Turbo Cx Polymerase (Agilent, Santa Clara, CA, United States), using the specific primers provided by Bios Scientific for enrichment. The library was finally purified with Agencourt AMPure XP beads (Beckman Coulter, Pasadena, CA, United States) according to manufacturer\'s instruction. The libraries were single-end sequenced using HiSeq High Output with read length of 50 bp. Base calling and sequence cleaning was performed with the standard Illumina software, then the clean reads were mapped to the *Arabidopsis* genome (Version: TAIR10) using Bismark v0.14.3 ([@bib29]) with default parameters; the PCR duplicates were removed, and the methylation information was obtained with bismark with cutoff 3. The DMRs were obtained using swDMR ([@bib55]) with window 200, step size 100, (left 1000, right 1000), the samples were compared using the Kruskal--Wallis analysis of variance with p-value \< 0.01. The DMRs were then annotated using BEDtools ([@bib41]).

CaLCuV pathogenesis assays {#s4-16}
--------------------------

3-week-old Col-0 wild-type, *kyp* mutant and *Flag-4Myc-KYP* complemented were infected by agroinfiltration of the CaLCuV infective clones of DNAA and DNAB pNSB1090 and pNSB1091 ([@bib2]); the progression of the disease was evaluated daily in terms of time of symptom development and the severity of the symptoms observed. The assays were replicated 3 times, 36 plants of each genotype were used per assay, grown in short day conditions (8 hr light/16 hr dark).

To assess systemic infection, we conducted virus infection assays using CaLCuV or CaLCuV Δ*trap* on thirty wild-type and thirty *kyp* mutant plants grown in short day condition (16 hr dark/8 hr light) at eight true leaves developmental stage, then we harvested nine to eleven newly emerged rosette leaves of each individual 18 days after inoculation ([Figure 9B](#fig9){ref-type="fig"}).
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**DOI:** [http://dx.doi.org/10.7554/eLife.06671.023](10.7554/eLife.06671.023)

10.7554/eLife.06671.024

###### 

List of proteins tested for interaction with TrAP.

**DOI:** [http://dx.doi.org/10.7554/eLife.06671.024](10.7554/eLife.06671.024)

10.7554/eLife.06671.025

###### 

CG methylation analysis of Col-0 wild type, *kyp* mutant, and TrAP transgenic plants.

**DOI:** [http://dx.doi.org/10.7554/eLife.06671.025](10.7554/eLife.06671.025)

10.7554/eLife.06671.026

###### 

CHG methylation analysis of Col-0 wild type, *kyp* mutant, and TrAP transgenic plants.

**DOI:** [http://dx.doi.org/10.7554/eLife.06671.026](10.7554/eLife.06671.026)

10.7554/eLife.06671.027

###### 

CHH methylation analysis of Col-0 wild type, *kyp* mutant, and TrAP transgenic plants.

**DOI:** [http://dx.doi.org/10.7554/eLife.06671.027](10.7554/eLife.06671.027)

10.7554/eLife.06671.028

###### 

List of primers used in this article.

**DOI:** [http://dx.doi.org/10.7554/eLife.06671.028](10.7554/eLife.06671.028)

Major datasets {#s6-1}
--------------

The following datasets were generated:

Castillo-González C, Zhang X, Liu X, Wang X, 2015,TrAP expression in Arabidopsis thaliana lead to global reprogramming of endogenous genes,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73495>,Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE73495).

Castillo-González C, Zhang X, Liu X, Wang X, 2015,Geminivirus-encoded TrAP suppressor inhibits the histone methyltransferase SUVH4/KYP to counter host defense,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73586>,Publicly available at the NCBI Gene Expression Omnibus (Accession no:GSE73586).

The following previously published dataset was used:

Du J, Johnson LM, Groth M, Feng S, Hale CJ, Li S, Vashisht AA, Gallego-Bartolome J, Wohlschlegel JA, Patel DJ, Jacobsen SE, 2014,Crystal structure of KRYPTONITE in complex with mCHH DNA and SAH,<http://www.rcsb.org/pdb/explore/explore.do?structureId=4QEN>,Publicly available at RCSB Protein Data Bank (Accession no. 4QEN).

10.7554/eLife.06671.029
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Geminivirus-encoded TrAP suppressor inhibits SUVH4/KYP activity to counter host defense" for consideration at *eLife*. Your article has been favorably evaluated by Detlef Weigel (Senior Editor) and three reviewers. All four discussed their comments before we reached this decision, and the editor has assembled the following comments to help you prepare a revised submission.

In your manuscript, you propose that a geminivirus encoded protein, TrAP, acts by interfering with the action of the SET domain histone methyltransferase SUVH4, a component of the plant host\'s transcriptional gene silencing machinery, providing a means that promotes virus survival in the arms race between virus and host. The topic is of broad interest given the conservation of HMTases in multicellular eukaryotes and the existence of other DNA viruses that affect animals, including humans. Your findings expand upon the previously proposed pleiotropic functions of TrAP proteins in suppression of TGS, such as adenosine kinase inhibition and SAMDC1 stabilisation. As well as illustrating a new role for TrAP during viral pathogenesis, your work could provide a useful tool for scientists, who could employ TrAP as a dominant inhibitor of H3K9me modification.

Your conclusions regarding the TrAP/SUNVH4 interaction are based on *TrAP* overexpression causing developmental defects reminiscent of certain epigenetic mutants, on physical interaction of TrAP with SUVH4 and inhibition of SUVH4 histone methyltransferase activity in vitro, and on SUVH4 effects on the viral genome. While there was in principle broad enthusiasm for the work among the reviewers, there were several substantial concerns that preclude acceptance of the work in its current form. However, we would be very interested in a substantially revised version, in which you provide:

1\) Whole-genome comparisons of DNA and H3K9 methylation in *suvh4* mutants and *TrAP* overexpressers.

2\) More evidence of direct interaction of SUVH4 and TrAP using co-IPs from complemented mutants.

The first major point of your manuscript concerns the interaction of TrAP with SUVH4. While we were convinced that TrAP can interact with SUVH4 in vitro, the in vivo data with overexpression constructs were less convincing. This is especially important considering there might be competition for binding to other SET domain proteins. As is, it is difficult to determine whether TrAP is indeed exerting its effect largely through SUVH4 rather than through any of the other 31+ *Arabidopsis* SET domain proteins or any of the other previously documented TrAP targets. The differences in phenotypes between *TrAP* overexpressers and *suvh4* mutants would suggest that the SUVH4 interaction is not the entire story. To further support the conclusion that TrAP specifically interacts with SUVH4 in vivo, you should conduct co-IP experiments using constructs expressed at endogenous levels. You already have a tagged version of SUVH4 expressed under its endogenous promoter and you have many plant lines expressing varying levels of TrAP, and these lines could be easily crossed. Even better, but not mandatory, would be affinity purification of the epitope tagged TrAP followed by mass spectrometry.

A second main point is that TrAP inhibits SUVH4. Again, the in vitro data are very good, but the in vivo data are less conclusive. For example, you demonstrate that constitutive expression of TrAP causes developmental defects reminiscent of mutations affecting various epigenetic modifications. However, such defects are not observed in the *suvh4* single mutant, nor the *suvh456* triple mutant, in which H3K9me levels are drastically reduced. In fact, you start out by comparing *TrAP* overexpressers with *lhp1* mutants. In any case, the phenotypic discrepancies suggests that expression of TrAP disrupts many biological processes not connected with SUVH4 or its closest homologs, and it raises the possibility that TrAP generally targets SET domain HMTases, a possibility that you acknowledge in the Discussion. In and of itself, such potential promiscuity of TrAP is not an issue, as it would be just as interesting if a single viral protein could inhibit many SET domain HMTases. However, to make the argument that part of the effects of TrAP are through inhibition of SUVH4, you should compare the effects of *TrAP* overexpression to the effects of *suvh4* mutants rather than the effects of other chromatin regulatory factors like LHP1. As there are very few genes mis-regulated in *suvh4* single mutants, you should compare global levels of DNA and H3K9 methylation in *TrAP* overexpressers to those observed in a *suvh4* mutant (or *suv456* triple mutants). We also note that LHP1 has been shown to bind H3K27me3 and that it is in the CURLY LEAF/Polycomb pathway, and that there is no evidence that LHP1 is related to SUVH4 function. It is not clear how these distinct effects can be easily reconciled, and it tends to make the current presentation appear disjointed. On the other hand, in [Figure 5](#fig5){ref-type="fig"} you show that *TrAP* overexpression tends to phenocopy methylation patterns of *suvh4* mutants at several endogenous loci, more so than the *lhp1* knockout. These issues would most easily be reconciled with whole-genome data, as suggested above.

A final main point concerns the hypothesis that TrAP-mediated inhibition of SUVH4 is a means of suppressing host defense. In support of this notion, you cite (and reproduce) previous data showing that *suvh4* mutants are more susceptible to geminivirus infection. You also show that SUVH4 associates with the geminivirus genome by ChIP. However H3K9me modification of the viral genome is largely unaffected by loss of SUVH4, and there is no evidence that the observed changes influence expression of viral genes. You should compare viral gene expression in wild type and *suvh4* mutants, to determine if transcriptional gene silencing by SUVH4 does indeed affect viral gene expression. If no change in expression is observed in the *suvh4* mutant, this would argue against the presented model and suggest TrAP is functioning via an alternative mechanism.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled "Geminivirus-encoded TrAP suppressor inhibits the histone methyltransferase SUVH4/KYP to counter host defense" for further consideration at *eLife*. Your revised article has been favorably evaluated by Detlef Weigel (Senior Editor) and three reviewers. The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below.

Specifically, we would like you to follow up as much as possible the suggestions of Reviewer 2, and also to provide BS-seq data.

Reviewer \#1:

The authors have addressed all my concerns. I understand the difficulties the authors had to address the major concern \#2 and I think that, even when the requested experiment would improve the manuscript its absence doesn\'t make the manuscript any weaker.

Reviewer \#2:

In the revised version of their manuscript, Castillo-Gonzalez et al. addressed several, but not all, of my main concerns. Regarding the in vivo relevance of the KYP-TrAP interaction, the authors conducted TrAP IP mass spectrometry experiments and found many peptides corresponding to KYP, confirming an interaction under biologically relevant conditions. A second concern was in regards to the H3K9me2 ChIP data supporting the conclusion that *TrAP* overexpression affects the activity of KYP in vivo. As outlined below, I remain concerned about the interpretation of this data. Regarding the final point, the role of KYP in regulating the expression of virus genes, the authors provide additional genetic evidence supporting a role of KYP in virus infection in a manner that is specifically connected to the *TrAP* gene. While this is not a direct assessment of the role of KYP in transcriptional regulation of viral genes, it does further support a link between TrAP, KYP, and viral defense. Taken together, the new experiments presented significantly strengthen the connection between KYP and TrAP, but the extent to which the TrAP protein modulates KYP HMTase activity at endogenous loci remains less clear.

ChIP data:

Castillo-Gonzalez present H3K9me ChIP data at a total of 14 endogenous loci in [Figure 5A-C](#fig5){ref-type="fig"} and conclude that ∼11/14 show reduced H3K9me levels in the *TrAP* overexpression lines which is in support of their hypothesis that TrAP inhibits KYP activity in vivo. However, as detailed below, it is not clear which, if any of the 10 genes tested in [Figure 5A and B](#fig5){ref-type="fig"} are normally marked H3K9me2, as would be expected for bona fide KYP targets. Without further clarification on these loci, that leaves the 4 transposons tested in [Figure 5C](#fig5){ref-type="fig"}, of which only two show a \>2x reduction in signal in the *TrAP* overexpression lines and the *kyp* mutants. Thus, while this data is in support of their conclusion that TrAP affects KYP activity in vivo, it is unclear how broadly TrAP is affecting KYP function. Inclusion of more loci known to be targets of KYP would significantly strengthen the conclusion that TrAP affects KYP function in vivo.

The ChIP data presented in [Figure 5A](#fig5){ref-type="fig"}/B should be separated out to indicate which genes are marked by each chromatin modification in WT plants. Each gene will be predominantly marked by only one modification (H3K4me, H3K9me, or H3K9me). Without knowing the levels of each modification in WT plants, the data cannot be fully interpreted as presented because the WT sample is artificially set to one. For example if a gene (like RDR1) is expressed and marked by H3K4me in Wt plants, but is not marked by H3K9me or H3K27me then a ChIP signal showing reduced H3K9me or H3K27me is likely noise rather than a real signal. This is a critical point in the paper, as they use this data make the statement that TrAP causes decreased H3K9me levels. In the subsection "TrAP reduced H3K9me2 repressive marks in vivo" they state: "specifically, eight out of 10 TrAP deregulated loci, including the flowering-promoting genes, displayed reduced H3K9me in the *TrAP* overexpression plants compared to WT plants...". However, in looking at available H3K9me2 data on the UCSC browser, these genes are largely devoid of H3K9me signal. To determine if there is H3K9me2 signal at the sites tested in [Figure 5A and B](#fig5){ref-type="fig"} in WT plants, and to determine if this signal is meaningfully reduced in the *TrAP* overexpression lines, the WT signal should not be normalized to one and instead should be presented as a % input (and/or normalized to H3) alongside the enrichment level at a gene without H3K9me (like actin). Such analysis should not require repeating the ChIP assays and thus can be done in the absence of a good lot of Abcam 1220 antibody. However, if these sites do not have sufficient H3K9me2 signal in Wt plants then testing additional loci will become necessary. In this case, looking at DNA methylation levels (even if they have been shown to be affected by other TrAP proteins the Bisaro lab) in Wt plants, *TrAP* overexpressor lines, and *kyp* mutants can serve in support of the authors' claims without relying on the Abcam H3K9me2 antibody.

Mass spectrometry data:

The text referring to the TrAP mass spectrometry data is quite brief and ambiguous as written. For example it is stated that 31 peptides uniquely match KYP, but it is unclear if these were only recovered in induced samples. Additional details should be provided in the text. For example in the response to the reviewers it is clearly stated that no peptides to KYP were identified in Col controls and that KYP was the most abundant hit from the mass spectrometry. It is not clear why these important details would be omitted from the text.

Reviewer \#3:

The manuscript has improved, and I can understand the difficulties with the H3K9me2 ChiP-seq, but I dont really agree with the reasoning to not do the BSseq. This is easy enough and while changes in DNA methylation might represent a downstream effect, the DNA methylation changes are well characterised in in suvh4 so they could still get a good idea of whether or not *TrAP* overexpression mimics loss of SUHV4 activity. The papers that the authors mention "Dr. David Bisaro\'s lab (Buchmann et al., [Figure 5B](#fig5){ref-type="fig"} in 2009 JV. 83 p5005-5013; and Raja, et al., [Figure 5C](#fig5){ref-type="fig"} in 2008, JV. 82 p8997-9007)" only perform BSseq at specific loci, not genome wide.

10.7554/eLife.06671.030

Author response

*The first major point of your manuscript concerns the interaction of TrAP with SUVH4. While we were convinced that TrAP can interact with SUVH4* in vitro*, the* in vivo *data with overexpression constructs were less convincing. This is especially important considering there might be competition for binding to other SET domain proteins. As is, it is difficult to determine whether TrAP is indeed exerting its effect largely through SUVH4 rather than through any of the other 31+* Arabidopsis *SET domain proteins or any of the other previously documented TrAP targets. The differences in phenotypes between* TrAP *overexpressers and* suvh4 *mutants would suggest that the SUVH4 interaction is not the entire story. To further support the conclusion that TrAP specifically interacts with SUVH4* in vivo*, you should conduct co-IP experiments using constructs expressed at endogenous levels. You already have a tagged version of SUVH4 expressed under its endogenous promoter and you have many plant lines expressing varying levels of TrAP, and these lines could be easily crossed. Even better, but not mandatory, would be affinity purification of the epitope tagged TrAP followed by mass spectrometry*.

Thanks for this point. To further confirm the interaction between SUVH4/TrAP, we have pursued proteomics analysis of the TrAP protein complexes by mass spectrometry. To this end we used stable *Arabidopsis thaliana* transgenic lines carrying the *XVE::Flag-Myc4-TrAP* construct. The XVE promoter is inducible with β-estradiol and allows for time-regulated expression of the viral protein. For this experiment we used 9-days old seedlings and we induced TrAP expression for 16h, then we purified the TrAP complexes through two-step affinity purification to study whether we could recover endogenous KYP protein, we performed this experiment in parallel with Col-0 plants. The mass spectrometry analysis recovered 31 unique peptides that matched specifically to KYP/SUVH4, none of which were found in the Col-0 control plants. Moreover, KYP was among the most abundant recovered proteins in the immunoprecipitated TrAP complexes. We have added these results in the new [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}. Thus, we are now very confident that KYP is a bona fide target of TrAP in vivo.

Importantly, we proposed in our manuscript that TrAP targets KYP to counter host defense. However, we did not mean that KYP is the only target of TrAP in the host. Indeed, we found by in vitro pull down assay that TrAP also interacts with the KYP paralogs SUVH2, 5, and 6 ([Figure 4--figure supplement 2](#fig4s2){ref-type="fig"}), and we also discussed the possibility of a more promiscuous effect of TrAP in the SET domain proteins predicted from the morphological phenotypes (in the Discussion). In fact, one aspect of our future effort is to examine how many SET domain containing proteins does TrAP target in the host, and how many of those targets are involved in host defense mechanisms. Also, we are working on additional potential targets recovered by proteomic analysis in our future study on this project.

*A second main point is that TrAP inhibits SUVH4. Again, the* in vitro *data are very good, but the* in vivo *data are less conclusive. For example, you demonstrate that constitutive expression of TrAP causes developmental defects reminiscent of mutations affecting various epigenetic modifications. However, such defects are not observed in the* suvh4 *single mutant, nor the* suvh456 *triple mutant, in which H3K9me levels are drastically reduced. In fact, you start out by comparing* TrAP *overexpressers with* lhp1 *mutants. In any case, the phenotypic discrepancies suggests that expression of TrAP disrupts many biological processes not connected with SUVH4 or its closest homologs, and it raises the possibility that TrAP generally targets SET domain HMTases, a possibility that you acknowledge in the Discussion. In and of itself, such potential promiscuity of TrAP is not an issue, as it would be just as interesting if a single viral protein could inhibit many SET domain HMTases. However, to make the argument that part of the effects of TrAP are through inhibition of SUVH4, you should compare the effects of* TrAP *overexpression to the effects of* suvh4 *mutants rather than the effects of other chromatin regulatory factors like LHP1. As there are very few genes mis-regulated in* suvh4 *single mutants, you should compare global levels of DNA and H3K9 methylation in* TrAP *overexpressers to those observed in a* suvh4 *mutant (or* suv456 *triple mutants). We also note that LHP1 has been shown to bind H3K27me3 and that it is in the CURLY LEAF/Polycomb pathway, and that there is no evidence that LHP1 is related to SUVH4 function. It is not clear how these distinct effects can be easily reconciled, and it tends to make the current presentation appear disjointed. On the other hand, in* [*Figure 5*](#fig5){ref-type="fig"} *you show that* TrAP *overexpression tends to phenocopy methylation patterns of* suvh4 *mutants at several endogenous loci, more so than the* lhp1 *knockout. These issues would most easily be reconciled with whole-genome data, as suggested above*.

This is an insightful point. It is true that TrAP transgenic plants phenocopy the morphology of mutants in the lhp1/leafy/polycomb pathway, but they also recapture the molecular phenotype of *suvh4*. We do not have to reconcile the relevance of LHP1 with SUVH4 (in fact, they are independent pathways in plants) since TrAP could target both pathways as stated in the discussion. We agree that our manuscript would be further improved if we could conduct whole-genome comparisons of H3K9 methylation in *suvh4* mutants and TrAP transgenic lines. With the advice as a guide, we have been actively pursuing this experiment. We prepared all materials and were ready for the ChIP-seq. However, we experienced an unexpected problem with the antibodies: as you know, the Abcam anti-H3K9me2 antibody (Ab1220) is the preferred antibody for ChIP-seq, and it is also the one we have successfully used before. Unfortunately, we ran out of our previous antibody (lot number 138716-4), and the newly purchased lots have not worked. We have screened the antibody from three lots already, with only one replacement barely immunoprecipitating H3K9me2 (signal 10^3^ fold less than the previous antibody). To date, we have spent many weeks doing all kinds of tests in all possible conditions. The conclusion is that we need to wait for a new lot of antibody from Abcam to be tested, and to perform the ChIP-seq if it is good.

I thought to mention that the reason for us to choose the Abcam antibody was that Abcam is known to produce good anti-H3K9m2 antibody. In a big collaborative project funded by NIH to screen varieties of antibodies from many vendors worldwide, to filter out noise and to find the best ones in the epigenetics field (Egelhofer, et al., 2011. An assessment of histone-modification antibody quality. 18:91-93), Abcam's ab1220 was reported as the best antibody for H3K9me2 ChIP. A website was provided for evaluation of the performance of each antibody (i.e. <http://compbio.med.harvard.edu/antibodies/targets/37> and

<http://compbio.med.harvard.edu/antibodies>). There are several other companies producing anti-H3K9me2 (i.e. Active motif; Diagenode; Hiroshi Kimura Lab; and millipore). Data from this project suggested that the antibodies from these vendors could not be used for ChIP-seq.

We understand the concerns brought up by the reviewers, and we agree that this experiment can improve our manuscript. Nonetheless, in order for us to present solid work to the scientific community, we require high-quality antibody for the ChIP-seq assay. While we could continue to test the new antibodies from different lots from Abcam and other sources, there is no guarantee of when and where we could obtain the high-quality anti-H3K9me2 antibody. However, to clarify the concern from this reviewer, we pursued an alternative genetic approach: First of all, we performed Southern blot analysis of virus titers in *kyp* mutant and Col-0 (new [Figure 8A-C](#fig8){ref-type="fig"}), and observed substantial increase of virus replication in the *kyp* mutant compared to wild-type plants. This result indicates that KYP is a major immune system for defense of virus. More importantly, we created a mutant virus without functional TrAP (CaLcV ∆TrAP), inoculated *kyp* mutants and Col-0 control. We found that control plants did not allow replication of CaLCuV ∆TrAP at a detectable level. In contrast, the *kyp* mutant plants displayed systemic virus accumulation to a certain extent (as shown in single-stranded viral DNA, New [Figure 8B-E](#fig8){ref-type="fig"}). Thus, these new results clearly boosted our model that TrAP targets KYP to counter host defense (also see response below).

Given our extensive genetic and biochemical evidence in the manuscript and new proteomics data, we believe that TrAP functionally targets KYP to counter host defense. At this stage, we would rather leave whole-genome comparisons of H3K9 methylation in *suvh4* mutants and *TrAP* transgenic lines for a follow-up work. Regarding comparison of DNA methylation levels in *suvh4* and *TrAP* transgenic lines, we would like to mention that this assay is not a priority for this manuscript -- the reason is that the impact of TrAP and SUVH4 on host and viral genomes has been reported by Dr. David Bisaro\'s lab (Buchmann et al., [Figure 5B](#fig5){ref-type="fig"} in 2009 JV. 83 p5005-5013; and Raja, et al., [Figure 5C](#fig5){ref-type="fig"} in 2008 JV. 82 p8997-9007). These results are well in line with our current work. Thus, additional sequencing might not increase the novelty and concept advance of our study; moreover, our biochemical study shows that TrAP mainly interacts with SET domain of KYP, which is the methyltransferase domain, and we presume that changes in histone methylation might be the primary cause for the TrAP function, while DNA methylation changes might be a downstream effect.

*A final main point concerns the hypothesis that TrAP-mediated inhibition of SUVH4 is a means of suppressing host defense. In support of this notion, you cite (and reproduce) previous data showing that* suvh4 *mutants are more susceptible to geminivirus infection. You also show that SUVH4 associates with the geminivirus genome by ChIP. However H3K9me modification of the viral genome is largely unaffected by loss of SUVH4, and there is no evidence that the observed changes influence expression of viral genes. You should compare viral gene expression in wild type and* suvh4 *mutants, to determine if transcriptional gene silencing by SUVH4 does indeed affect viral gene expression. If no change in expression is observed in the* suvh4 *mutant, this would argue against the presented model and suggest TrAP is functioning via an alternative mechanism*.

Another insightful point. So far, we have provided evidence of the effect of KYP levels on the progression of CaLCuV infection in *Arabidopsis*, as the *kyp* mutants are hypersensitive, the complemented lines are as sensitive as the wild type, and the over expression lines are more resistant to infection. Moreover, we have shown that KYP expression affects the methylation status of the viral chromatin. Together, these data point to a direct effect of KYP in the pathogenesis of CaLCuV.

With the comment as a guidance, we have performed Southern blots to determine the populations of the viral DNA in the infected plants, and we have now shown that *kyp* mutant plants not only show more severe symptoms of infection, but also they accumulate the virus titers at more than 20-fold higher level than that in the wild type plants. The virus accumulation and systemic infection entails TrAP protein, as it is required for the expression of the late genes (coat protein and nuclear shuttle protein) that are necessary for the accumulation of the infective ssDNA particle. Most importantly, we have engineered a TrAP null mutant virus and we have performed infection studies in both the wild type and *kyp* mutant plants. As previously shown, begomoviruses deficient in TrAP are unable to cause systemic infection in wild type hosts; however, *kyp* mutant hosts can sustain systemic infection of this virus, although at low levels (Please refer to our response above).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*Specifically, we would like you to follow up as much as possible the suggestions of Reviewer 2, and also to provide BS-seq data*.

Reviewer \#1:

*The authors have addressed all my concerns. I understand the difficulties the authors had to address the major concern \#2 and I think that, even when the requested experiment would improve the manuscript its absence doesn\'t make the manuscript any weaker*.

Reviewer \#2:

*In the revised version of their manuscript, Castillo-Gonzalez et al. addressed several, but not all, of my main concerns. Regarding the* in vivo *relevance of the KYP-TrAP interaction, the authors conducted TrAP IP mass spectrometry experiments and found many peptides corresponding to KYP, confirming an interaction under biologically relevant conditions. A second concern was in regards to the H3K9me2 ChIP data supporting the conclusion that* TrAP *overexpression affects the activity of KYP* in vivo*. As outlined below, I remain concerned about the interpretation of this data. Regarding the final point, the role of KYP in regulating the expression of virus genes, the authors provide additional genetic evidence supporting a role of KYP in virus infection in a manner that is specifically connected to the* TrAP *gene. While this is not a direct assessment of the role of KYP in transcriptional regulation of viral genes, it does further support a link between TrAP, KYP, and viral defense. Taken together, the new experiments presented significantly strengthen the connection between KYP and TrAP, but the extent to which the TrAP protein modulates KYP HMTase activity at endogenous loci remains less clear*.

ChIP data:

*Castillo-Gonzalez present H3K9me ChIP data at a total of 14 endogenous loci in* [*Figure 5A-C*](#fig5){ref-type="fig"} *and conclude that ∼11/14 show reduced H3K9me levels in the* TrAP *overexpression lines which is in support of their hypothesis that TrAP inhibits KYP activity* in vivo*. However, as detailed below, it is not clear which, if any of the 10 genes tested in* [*Figure 5A and B*](#fig5){ref-type="fig"} *are normally marked H3K9me2, as would be expected for bona fide KYP targets. Without further clarification on these loci, that leaves the 4 transposons tested in* [*Figure 5C*](#fig5){ref-type="fig"}*, of which only two show a \>2x reduction in signal in the* TrAP *overexpression lines and the* kyp *mutants. Thus, while this data is in support of their conclusion that TrAP affects KYP activity* in vivo*, it is unclear how broadly TrAP is affecting KYP function. Inclusion of more loci known to be targets of KYP would significantly strengthen the conclusion that TrAP affects KYP function* in vivo.

This is a very important point. Obviously, we missed the opportunity of presenting our point clearly in the previous versions. Here in this version, we emphasized this critical point.

Briefly, we have included five transposable elements known to be targets of KYP, all of which showed greater than 2-fold decrease in our experiments (new [Figure 6A](#fig6){ref-type="fig"}). On the other hand, the comprehensive body of work published by Dr. Steven Jacobsen group on chromatin structure and regulation (Zhang et al., Genome-wide analysis of mono-, di- and trimethylation of histone H3 lysine 4 in *Arabidopsis thaliana*, Genome Biology, 2009; Bernatavichute et al., Genome-Wide Association of Histone H3 Lysine Nine Methylation with CHG DNA Methylation in *Arabidopsis thaliana*, PLoS ONE, 2008; Zhang et al., PLoS Biology, 2007) allowed us to pinpoint the specific histone modifications (H3K9me2, H3K27me3 and H3K4me3) on the genome and to provide a guide for selection of the regions for ChIP-qPCR (see [Author response image 1](#fig10){ref-type="fig"}).10.7554/eLife.06671.031Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.06671.031](10.7554/eLife.06671.031)

In fact, the criteria we used to select the loci for RT-qPCR and ChIP-qPCR were: 1) their transcription was significantly affected by the expression of the TrAP transgene ([Figure 2](#fig2){ref-type="fig"}); and 2) H3K9me2 mark have been found in the loci. For example, FTM1, FT, AGL9, MFT, PRE1 and AT4G17810 all harbor H3K9me2 marks ([Author response image 1](#fig10){ref-type="fig"}).

We should also mention that there might be few cases in which our data was not fully consistent with the published work. The reason is that plant materials in our experiments differ from the materials used in previous studies. We used 11 days-old seedlings grown in short day conditions (8h light/ 16h dark), while some of the data reported was obtained from 3 weeks old adult plants grown under constant light (i.e. H3K9me2 and H3K4me3), or from 10-14 days-old seedlings grown in long day condition (16h light/ 8h dark) (i.e. H3K27me3). These differences imply a huge disparity in the developmental stage of the samples, as H3K9me2 and H3K4me3 mark were measured from flowered adult plants. Taking into consideration that we focused on flowering genes, it is not surprising that some differences between our data and others' exist.

*The ChIP data presented in* [*Figure 5A*](#fig5){ref-type="fig"}*/B should be separated out to indicate which genes are marked by each chromatin modification in WT plants. Each gene will be predominantly marked by only one modification (H3K4me, H3K9me, or H3K9me). Without knowing the levels of each modification in WT plants, the data cannot be fully interpreted as presented because the WT sample is artificially set to one. For example if a gene (like RDR1) is expressed and marked by H3K4me in Wt plants, but is not marked by H3K9me or H3K27me then a ChIP signal showing reduced H3K9me or H3K27me is likely noise rather than a real signal. This is a critical point in the paper, as they use this data make the statement that TrAP causes decreased H3K9me levels. In the subsection "TrAP reduced H3K9me2 repressive marks* in vivo*" they state: "specifically, eight out of 10 TrAP deregulated loci, including the flowering-promoting genes, displayed reduced H3K9me in the* TrAP *overexpression plants compared to WT plants...". However, in looking at available H3K9me2 data on the UCSC browser, these genes are largely devoid of H3K9me signal. To determine if there is H3K9me2 signal at the sites tested in* [*Figure 5A and B*](#fig5){ref-type="fig"} *in WT plants, and to determine if this signal is meaningfully reduced in the* TrAP *overexpression lines, the WT signal should not be normalized to one and instead should be presented as a % input (and/or normalized to H3) alongside the enrichment level at a gene without H3K9me (like actin). Such analysis should not require repeating the ChIP assays and thus can be done in the absence of a good lot of Abcam 1220 antibody. However, if these sites do not have sufficient H3K9me2 signal in Wt plants then testing additional loci will become necessary. In this case, looking at DNA methylation levels (even if they have been shown to be affected by other TrAP proteins the Bisaro lab) in Wt plants,* TrAP *overexpressor lines, and* kyp *mutants can serve in support of the authors' claims without relying on the Abcam H3K9me2 antibody*.

This is another insightful point; and thanks to this reviewer for guiding us on how to present our ChIP data in a more accurate way.

First, based on the advice from this reviewer, we recalculated our ChIP-qPCR and completely reformatted the data taking into account the background signal, by redoing qPCR using the remaining ChIP DNA from the original experiments. In the new figures, each histone modification is shown separately. Also, the data is presented as enrichment relative to tubulin (TUB8) or relative to input alongside to TUB8 (this is particular for H3K9me2, since the TUB8 signal was extremely low and the values relative to TUB8 resulted in an exorbitant range). We would like to emphasize that our remaining ChIP-DNA from previous experiments only allowed us to repeat 7 of 12 protein-coding genes in our original manuscript, and the 5 transposable elements presented in the current version.

We would like to reiterate that the previously published H3K9me2 ChIP-seq data are obtained using plants at a developmental stage different from ours as stated above, and this fact could cause differences at the chromatin level that may render the data not readily comparable. For instance, the reported H3K9me2 marks at some of our target genes are low in the 3-week old plants, but one could not imply that they do not exist at the seedling stage. As an additional case, the published H3K27me3 (obtained from seedlings) and H3K4me3 (obtained from adult plants) available datasets, if directly compared, might mislead us to conclude that both modifications coexist at the flowering genes.

*Mass spectrometry data*:

*The text referring to the TrAP mass spectrometry data is quite brief and ambiguous as written. For example it is stated that 31 peptides uniquely match KYP, but it is unclear if these were only recovered in induced samples. Additional details should be provided in the text. For example in the response to the reviewers it is clearly stated that no peptides to KYP were identified in Col controls and that KYP was the most abundant hit from the mass spectrometry. It is not clear why these important details would be omitted from the text*.

We stated this point in the previous point-to-point response letter; and now we have moved this critical information in the main text.

Reviewer \#3:

*The manuscript has improved, and I can understand the difficulties with the H3K9me2 ChiP-seq, but I dont really agree with the reasoning to not do the BSseq. This is easy enough and while changes in DNA methylation might represent a downstream effect, the DNA methylation changes are well characterised in in suvh4 so they could still get a good idea of whether or not* TrAP *overexpression mimics loss of SUHV4 activity. The papers that the authors mention "Dr. David Bisaro\'s lab (Buchmann et al.,* [*Figure 5B*](#fig5){ref-type="fig"} *in 2009 JV. 83 p5005-5013; and Raja, et al.,* [*Figure 5C*](#fig5){ref-type="fig"} *in 2008, JV. 82 p8997-9007)" only perform BSseq at specific loci, not genome wide*.

As requested, we have performed whole genome bisulfite sequencing in our Col-0 wild type, *suvh4/kyp*, and 35S-TrAP plants. The new result is now included in the new subsection "TrAP decreases CHH DNA methylation" and new [Figure 7](#fig7){ref-type="fig"}, [Figure 7--figure supplement 1](#fig7s1){ref-type="fig"}, and the [Supplementary files 5, 6, and 7](#SD5-data SD6-data SD7-data){ref-type="supplementary-material"}.

We found that *TrAP* overexpression did not affect CHG methylation; however, it reduced CHH methylation in gene rich regions that were almost completely overlapped with the *suvh4* mutant. These regions included FT, CUC1, and AT4G17810, in accordance with our reported loss of H3K9me2 enrichment in TrAP transgenic lines and *suvh4* mutants. Our new result is a bit surprising, but more exciting, that is to say, CHH and CHG could be regulated separately -- it is known that CMT2 -- the main CHH DNA methyltransferase -- has greater affinity for H3K9me2 over H3K9me1. Other non-CG methyltransferases, such as CMT3 (which catalyzes CHG methylation) do not show binding preference among different methylation levels in the histone tail. We therefore envision methylation at CHH sites to be more sensitive to changes in H3K9me2 methylation than CHG. In all, our data is consistent with decrease in H3K9me2, which could be explained by partial inhibition of SUVH4 activity.
